var title_f4_2_4128="North American paper wasps";
var content_f4_2_4128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70439&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    North American paper wasps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from American Academy of Allergy and Immunology, Monograph on Insect Allergy, 3rd edition, Levine MI, Lockey RF (Eds), 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4128=[""].join("\n");
var outline_f4_2_4128=null;
var title_f4_2_4129="Extraarticular fracture of the first metacarpal";
var content_f4_2_4129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50297%7EEM%2F63101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50297%7EEM%2F63101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extraarticular fracture of the first metacarpal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a type III fracture of the proximal 1st metacarpal with characteristic sparing of the articular surface. Significant shortening of the metacarpal is also apparent in this view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced thumb metacarpal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this radiograph a nondisplaced fracture of the&nbsp;thumb metacarpal distal to the carpal metacarpal joint is seen. This is a nondisplaced type III fracture of the first metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4129=[""].join("\n");
var outline_f4_2_4129=null;
var title_f4_2_4130="Chronic GVHD - range of motion";
var content_f4_2_4130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep sclerosis leading to joint contractures limited the ability to extend the fingers in this patient with chronic GVHD (\"prayer sign\"). The overlying skin appears normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4130=[""].join("\n");
var outline_f4_2_4130=null;
var title_f4_2_4131="Patient information: How to tell when labor starts (The Basics)";
var content_f4_2_4131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33873\">",
"         Patient information: Managing pain during labor and delivery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/21/39249\">",
"         Patient information: Preterm premature rupture of membranes (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/52/35650\">",
"         Patient information: Preterm labor (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: How to tell when labor starts (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/how-to-tell-when-labor-starts-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H298413174\">",
"      <span class=\"h1\">",
"       What is labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Labor is the way a woman&rsquo;s body prepares to give birth. Labor usually starts on its own between 37 and 42 weeks of pregnancy. A woman&rsquo;s &ldquo;due date&rdquo; is at 40 weeks.",
"     </p>",
"     <p>",
"      A pregnancy that lasts 37 to 42 weeks is called a &ldquo;term&rdquo; pregnancy. When labor starts before 37 weeks, doctors call it &ldquo;preterm&rdquo; labor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413181\">",
"      <span class=\"h1\">",
"       What are the signs that labor is starting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The different signs that labor is starting can include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The baby moves lower (or &ldquo;drops&rdquo;) in your belly.",
"       </li>",
"       <li>",
"        You have increased vaginal discharge that is thick, mucus-like, or slightly bloody. (Vaginal discharge is the term doctors use to describe the fluid that comes out of the vagina.) The increased vaginal discharge is sometimes called a &ldquo;mucus plug&rdquo; or a &ldquo;bloody show.&rdquo;",
"       </li>",
"       <li>",
"        Your water breaks. During pregnancy, your baby is in a sac in your uterus and surrounded by a fluid called &ldquo;amniotic fluid.&rdquo; This sac will break open sometime before your baby is born. When it breaks open, the fluid inside comes out of your vagina. This can feel like a gush or trickle of fluid.",
"       </li>",
"       <li>",
"        You have low back pain or belly cramps.",
"       </li>",
"       <li>",
"        You start having contractions. During a contraction, the uterus tightens. This can be painful and make your belly feel hard. After a contraction, the uterus relaxes and the pain goes away. Some women have &ldquo;Braxton Hicks contractions&rdquo; or &ldquo;false labor contractions.&rdquo; These feel like contractions, but they are not true contractions. They do not mean that you are in labor.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413188\">",
"      <span class=\"h1\">",
"       How can I tell if I&rsquo;m having true contractions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be hard to tell if you are having true contractions or Braxton Hicks contractions. But here are some ways to help tell the difference.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        True contractions come every few minutes and get more frequent over time. Braxton Hicks contractions can come every few minutes, but they don&rsquo;t get more frequent over time.",
"       </li>",
"       <li>",
"        True contractions don&rsquo;t go away, even when you rest. Braxton Hicks contractions usually go away when you rest.",
"       </li>",
"       <li>",
"        True contractions will get stronger and more painful over time. Braxton Hicks contractions usually don&rsquo;t get stronger or more painful over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you are still not sure whether you are having true contractions, call your doctor or midwife.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413195\">",
"      <span class=\"h1\">",
"       What should I do if I start having contractions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you start having contractions, you should time them to see how far apart they are. That way, you can tell if they get more frequent.",
"     </p>",
"     <p>",
"      You can time your contractions by writing down the time when each contraction starts. If you have a clock with a second hand, you can also time how long each contraction lasts. Your doctor or midwife will want to know how far apart your contractions are and how long they last.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413202\">",
"      <span class=\"h1\">",
"       When should I call my doctor or midwife?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or midwife if you think you are in labor. You should also call if ANY of the following things happen:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have blood, mucus, or fluid leaking from your vagina.",
"       </li>",
"       <li>",
"        You have 6 or more contractions in 1 hour. (That means your contractions are 10 minutes apart or less.)",
"       </li>",
"       <li>",
"        Your contractions are getting stronger and are painful.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or midwife will probably want to see you to do an exam. To tell if you are in labor, he or she will check your cervix to see if it is opening (&ldquo;dilated&rdquo;) and thinning out. He or she will see how frequent your contractions are. He or she might also do other tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413209\">",
"      <span class=\"h1\">",
"       What if my labor starts too soon?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you start having any symptoms of labor before 37 weeks, call your doctor right away. He or she might want to give you medicine to try to stop your labor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413216\">",
"      <span class=\"h1\">",
"       What if my labor doesn&rsquo;t start on its own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your labor doesn&rsquo;t start on its own, your doctor will talk to you about your options. He or she might try to start your labor with medicines. This is called &ldquo;inducing labor.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413223\">",
"      <span class=\"h1\">",
"       How long will my labor last?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If it&rsquo;s your first baby, your labor will probably last for many hours. If it&rsquo;s not your first baby, your labor will probably be shorter.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H298413286\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=see_link\">",
"       Patient information: Managing pain during labor and delivery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=see_link\">",
"       Patient information: Preterm premature rupture of membranes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       Patient information: Preterm labor (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/2/4131?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16909 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-CCB85E928E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4131=[""].join("\n");
var outline_f4_2_4131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413174\">",
"      What is labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413181\">",
"      What are the signs that labor is starting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413188\">",
"      How can I tell if I&rsquo;m having true contractions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413195\">",
"      What should I do if I start having contractions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413202\">",
"      When should I call my doctor or midwife?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413209\">",
"      What if my labor starts too soon?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413216\">",
"      What if my labor doesn&rsquo;t start on its own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413223\">",
"      How long will my labor last?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H298413286\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=related_link\">",
"      Patient information: Preterm premature rupture of membranes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_2_4132="Dermatophyte KOH";
var content_f4_2_4132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatophyte potassium hydroxide preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Septate hyphae are visible on a background of squamous cells in this potassium hydroxide preparation taken from a lesion of tinea corporis. Potassium hydroxide preparations from tinea pedis and tinea cruris have a similar appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4132=[""].join("\n");
var outline_f4_2_4132=null;
var title_f4_2_4133="Systemic treatment of recurrent meningioma";
var content_f4_2_4133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Systemic treatment of recurrent meningioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4133/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4133/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4133/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4133/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4133/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4133/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/2/4133/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H444763133\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas account for approximately one-third of primary central nervous system tumors (",
"    <a class=\"graphic graphic_table graphicRef81566 \" href=\"UTD.htm?6/44/6862\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72275 \" href=\"UTD.htm?28/44/29391\">",
"     figure 1",
"    </a>",
"    ). Surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy (RT) constitutes the initial therapeutic approach. Furthermore, surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT are able to control disease in some patients with recurrence.",
"   </p>",
"   <p>",
"    Despite the appropriate use of surgery and RT for initial management and management of recurrent disease, there is a subset of patients in whom disease cannot be controlled with these approaches. Experience with systemic therapy is limited, and most data are from observational studies. Although a number of agents have been studied, none have an established role in prolonging progression-free or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available data for systemic therapy is reviewed here. Topics dealing with other aspects of meningioma management include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link\">",
"       \"Meningioma: Epidemiology, risk factors, and pathology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link\">",
"       \"Treatment of benign (WHO grade I) meningioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42389?source=see_link\">",
"       \"Atypical and malignant meningiomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763147\">",
"    <span class=\"h1\">",
"     HORMONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic evidence suggests that there is a link between hormonal factors and the development or progression of meningiomas. Progesterone and androgen receptors are expressed on approximately two-thirds of meningiomas and estrogen receptor is expressed on approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link&amp;anchor=H627075249#H627075249\">",
"     \"Meningioma: Epidemiology, risk factors, and pathology\", section on 'Hormonal factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibition of these receptors has not been demonstrated to alter the natural history of recurrent meningiomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Progesterone receptor inhibition",
"      </strong>",
"      &ndash; Small studies with the progesterone receptor inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      suggested that this agent resulted in objective improvement in 25 to 30 percent of patients with unresectable meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. However, a multicenter cooperative group phase III trial failed to demonstrate any benefit from treatment with mifepristone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/6\">",
"       6",
"      </a>",
"      ]. In this trial, 180 patients were randomly assigned to either mifepristone or placebo. There was no improvement in median progression-free survival (10 versus 12 months). The lack of activity in this trial may have been due to loss of expression of progesterone receptor in patients with advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Estrogen receptor inhibitors",
"      </strong>",
"      &ndash; Two studies have evaluated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in patients inoperable meningiomas, without definitive evidence of clinical activity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In the larger of these, a Southwest Oncology Group study, 21 patients were treated; only one partial response was observed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/7\">",
"       7",
"      </a>",
"      ]. The poor response rate may reflect the low rate of expression of estrogen receptor in patients with meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Androgen receptor inhibitors",
"      </strong>",
"      &ndash; No formal clinical studies have been reported with antiandrogens. Experience with a limited number of patients has not demonstrated useful clinical activity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763154\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of chemotherapy agents has been studied in small series, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/9\">",
"     9",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/10\">",
"     10",
"    </a>",
"    ] and combinations such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/11\">",
"     11",
"    </a>",
"    ]. Results with these approaches have not provided evidence of significant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensively studied agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    . Early studies reported imaging evidence of tumor shrinkage or seemingly prolonged stable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"     2",
"    </a>",
"    ]. However, these observations were not confirmed in a phase II study conducted by the Southwest Oncology Group (S9811) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/9\">",
"     9",
"    </a>",
"    ]. There were no objective responses in the 29 patients with measurable, biopsy-proven benign meningiomas, although the median progression-free survival was 27 months and the three-year progression-free survival rate was 43 percent. Whether this represents an effect on the natural history of benign meningiomas is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763161\">",
"    <span class=\"h1\">",
"     INTERFERON ALFA-2B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     Interferon alfa-2b",
"    </a>",
"    (IFNa) inhibits the growth of meningioma cells exposed to mitotic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/12\">",
"     12",
"    </a>",
"    ], and preliminary reports suggested that IFNa had clinical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive experience with IFNa comes from a prospective phase II study in which 35 patients with recurrent grade I intracranial meningiomas were treated with IFNa (10 million units subcutaneously every other day) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/15\">",
"     15",
"    </a>",
"    ]. All patients had received prior surgery and RT, and 34 had received prior systemic therapy. No objective responses were observed, although 26 patients (74 percent) had stable disease for at least 12 weeks. Median overall survival was eight months.",
"   </p>",
"   <p>",
"    The extent to which these results indicate clinical activity for IFNa is unclear, since grade I meningiomas are generally slow growing and multiple scans may be required to demonstrate significant changes in tumor size. Furthermore, the median overall survival of eight months suggests that this was a highly selected group of patients with a particularly poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763168\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin receptors are expressed in approximately 90 percent of meningiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"     2",
"    </a>",
"    ]. Case reports suggested that therapy targeted to this pathway might have therapeutic usefulness for patients with recurrent, unresectable meningiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective pilot study treated 16 patients with a long-acting formulation of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/19\">",
"     19",
"    </a>",
"    ]. All patients had recurrent, progressive meningioma and at least six months had passed since prior radiation therapy. All of the meningiomas expressed somatostatin receptors as demonstrated by a radiolabeled octreotide scan. Partial responses were observed in five patients (31 percent) and another five patients had stable disease. The median survival was eight months.",
"   </p>",
"   <p>",
"    Another somatostatin analog,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/21/27989?source=see_link\">",
"     pasireotide",
"    </a>",
"    (SOM230C), is currently being evaluated in a multicenter, phase II trial in patients with recurrent, progressive meningioma (NCT00859040) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763175\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing understanding of the cell signaling pathways has led to the identification of other pathways and potential targets for therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"     2",
"    </a>",
"    ]. Several of these approaches are being evaluated in meningioma patients requiring systemic therapy. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Platelet derived growth factor",
"      </strong>",
"      &ndash; Platelet derived growth factor (PDGF) stimulates tumor cell growth in a number of tumors. PDGF receptors are commonly expressed on the cell surface of meningiomas.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      , an inhibitor of the PDGF receptors, has been evaluated in phase II studies either alone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/21\">",
"       21",
"      </a>",
"      ] or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/22\">",
"       22",
"      </a>",
"      ]. No objective responses or prolongation in progression-free survival were identified by imaging in either study.",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermal growth factor",
"      </strong>",
"      &ndash; Epidermal growth factor receptor (EGFR) is overexpressed on more than 60 percent of meningiomas [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"       2",
"      </a>",
"      ]. The EGFR tyrosine kinase inhibitors",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      were evaluated in two studies conducted by NABTC [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/23\">",
"       23",
"      </a>",
"      ]. No objective responses were observed and the studies concluded that these agents did not have clinically useful activity.",
"     </li>",
"     <li>",
"      <strong>",
"       Angiogenesis inhibition",
"      </strong>",
"      &ndash; Meningiomas are vascular tumors, suggesting that inhibition of angiogenesis might be a clinically useful approach [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"       2",
"      </a>",
"      ]. In a retrospective analysis, 12 of 14 patients with recurrent meningioma treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , a monoclonal antibody that binds vascular endothelial growth factor (VEGF), were progression-free at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/24\">",
"       24",
"      </a>",
"      ]. In another study of 15 patients treated with bevacizumab for atypical or anaplastic meningiomas, the best response observed was stable disease, and the median progression-free survival was six months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4133/abstract/25\">",
"       25",
"      </a>",
"      ]. Additional studies with bevacizumab are required. Other agents being investigated to target angiogenesis include vatalanib and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444763182\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no established systemic therapy that has been shown effectively treat recurrent meningioma or to increase survival. Whenever possible, such patients should be enrolled into formal clinical protocols.",
"     </li>",
"     <li>",
"      For patients who are not eligible for inclusion on a protocol, options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      or possibly a VEGFR inhibitor, although there is no evidence that these agents affect the natural history of recurrent meningioma.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/1\">",
"      Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009; 9:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/2\">",
"      Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol 2010; 99:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/3\">",
"      Koide SS. Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 1998; 43:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/4\">",
"      Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/5\">",
"      Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006; 24:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/6\">",
"      Grunberg SM, Rankin C, Townsend J. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc Am Soc Clinical Oncol 2001; 20:56a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/7\">",
"      Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993; 15:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/8\">",
"      Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas--a pilot study. Surg Neurol 1985; 24:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/9\">",
"      Swinnen LJ, Rankin C, Rushing EJ. Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma. J Clin Oncol 2009; 27:15s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/10\">",
"      Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004; 62:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/11\">",
"      Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996; 84:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/12\">",
"      Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991; 27:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/13\">",
"      Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997; 40:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/14\">",
"      Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001; 7:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/15\">",
"      Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 2008; 113:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/16\">",
"      Garc&iacute;a-Luna PP, Relimpio F, Pumar A, et al. Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 1993; 37:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/17\">",
"      R&uuml;nzi MW, Jaspers C, Windeck R, et al. Treatment of meningioma with octreotide. Lancet 1989; 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/18\">",
"      Jaffrain-Rea ML, Minniti G, Santoro A, et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 1998; 100:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/19\">",
"      Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007; 69:969.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database: file://www.clinicaltrials.gov/ (Accessed on October 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/21\">",
"      Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009; 11:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/22\">",
"      Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec&reg; plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012; 106:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/23\">",
"      Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010; 96:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/24\">",
"      Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012; 109:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4133/abstract/25\">",
"      Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012; 109:187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15693 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4133=[""].join("\n");
var outline_f4_2_4133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H444763182\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763133\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763147\">",
"      HORMONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763154\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763161\">",
"      INTERFERON ALFA-2B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763168\">",
"      SOMATOSTATIN ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763175\">",
"      MOLECULARLY TARGETED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444763182\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15693|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/44/29391\" title=\"figure 1\">",
"      Incidence rates of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6862\" title=\"table 1\">",
"      CBTRUS incidence of primary CNS tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42389?source=related_link\">",
"      Atypical and malignant meningiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_2_4134="Examination metacarpal malrotation";
var content_f4_2_4134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73269%7EEM%2F71612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73269%7EEM%2F71612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination for malrotation of metacarpals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The metacarpophalangeal and proximal interphalangeal joints are flexed to 90 degrees in this photograph of two normal hands. Axial lines drawn through the middle and distal phalanges of the 2nd through 5th digits are nearly parallel and converge near the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malrotation due to metacarpal fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axes of the fingers normally converge when the metacarpophalangeal and proximal interphalangeal joints are both flexed. In this photograph, while the 2nd, 3rd, and 4th fingers converge as they should, the 5th does not. The divergence of the 5th digit is the result of a 5th metacarpal shaft fracture complicated by malrotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Burroughs, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4134=[""].join("\n");
var outline_f4_2_4134=null;
var title_f4_2_4135="Hypertrophic lichen planus2";
var content_f4_2_4135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypertrophic lichen planus. Darkly pigmented hypertrophic lesions are present on the pretibial shaft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4135=[""].join("\n");
var outline_f4_2_4135=null;
var title_f4_2_4136="Cefazolin: Drug information";
var content_f4_2_4136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefazolin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/26/32163?source=see_link\">",
"    see \"Cefazolin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"    see \"Cefazolin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16329907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefazolin For Injection;",
"     </li>",
"     <li>",
"      Cefazolin For Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (First Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M., I.V.: 1000-1500 mg every 8 hours, depending on severity of infection; maximum: 12",
"     <b>",
"      g",
"     </b>",
"     daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cholecystitis, mild-to-moderate:",
"     </b>",
"     I.V.: 1000-2000 mg every 8 hours for  4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endocarditis due to MSSA (without prosthesis) (unlabeled use):",
"     </b>",
"     I.V.: 2000 mg every 8 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Recommended for penicillin-allergic (nonanaphylactoid) patients (Baddour, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Group B streptococcus (neonatal prophylaxis):",
"     </b>",
"     I.V.: 2000 mg once, then 1000 mg every 8 hours until delivery (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community-acquired, mild-to-moderate (in combination with metronidazole):",
"     </b>",
"     I.V.:  1000-2000 mg every 8 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Moderate-to-severe infections:",
"     </b>",
"     I.V.: 500-1000 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild infection with gram-positive cocci:",
"     </b>",
"     I.V.: 250-500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Perioperative prophylaxis:",
"     </b>",
"     I.M., I.V.: 1000-2000 mg within 60 minutes prior to surgery (may repeat in 2-5 hours intraoperatively); followed by 500-1000 mg every 6-8 hours for 24 hours postoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cardiothoracic surgery:",
"     </i>",
"     1000 mg (see \"",
"     <b>",
"      Note",
"     </b>",
"     \") within 60 minutes prior to incision, followed by 1000 mg at sternotomy and 1000 mg after cardiopulmonary bypass; may continue 1000 mg every 6 hours for 24-48 hours postoperatively (Eagle, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For patients weighing &gt;60 kg, the Society of Thoracic Surgeons recommends a preoperative dose of 2000 mg administered within 60 minutes of skin incision. If the surgical incision remains open in the operating room, follow with 1000 mg every 3-4 hours unless cardiopulmonary bypass is to be discontinued within 4 hours then delay administration (Engelman, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cholecystectomy:",
"     </i>",
"     1000-2000 mg every 8 hours, discontinue within 24 hours unless infection outside gallbladder suspected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Total joint replacement:",
"     </i>",
"     1000 mg 1 hour prior to the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pneumococcal pneumonia:",
"     </b>",
"     I.V.: 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     I.M., I.V.: 1000 mg 30-60 minutes before procedure.",
"     <b>",
"      Note:",
"     </b>",
"     Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection,",
"     </b>",
"     <b>",
"      <i>",
"       Staphylococci",
"      </i>",
"     </b>",
"     <b>",
"      (oxacillin-susceptible):",
"     </b>",
"     I.V.: 1000-2000 mg every 8 hours for 2-6 weeks (in combination with rifampin) followed by oral antibiotic treatment and suppressive regimens (Osmon, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe infection:",
"     </b>",
"     I.V.: 1000-1500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      UTI (uncomplicated):",
"     </b>",
"     I.M., I.V.: 1000 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"      see \"Cefazolin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"     I.M., I.V.: Children &gt;1 month: 25-100 mg/kg/day divided every 6-8 hours; maximum: 6 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP) (IDSA/PIDS, 2011), moderate-to-severe infection,",
"      <b>",
"       <i>",
"        S. aureus",
"       </i>",
"      </b>",
"      (methicillin-susceptible) (preferred):",
"     </b>",
"     Infants &gt;3 months and Children: I.M., I.V.: 150 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis against infective endocarditis (unlabeled use):",
"     </b>",
"     Infants and Children: I.M., I.V.: 50 mg/kg 30-60 minutes before procedure; maximum dose: 1000 mg. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     35-54 mL/minute: Administer full dose in intervals of &ge;8 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     11-34 mL/minute: Administer 50% of usual dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;10 mL/minute: Administer 50% of usual dose every 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): 500-1000 mg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     use 1000-2000 mg every 48-72 hours (Heintz, 2009);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of  3 times/week, complete IHD sessions. Alternatively, may administer 15-20 mg/kg (maximum dose: 2000 mg) after dialysis without regularly scheduled dosing (Ahern, 2003; Sowinski, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 0.5 g every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: Loading dose of 2000 mg followed by 1000-2000 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD/CVVHDF: Loading dose of 2000 mg followed by either 1000 mg every 8 hours",
"     <b>",
"      or",
"     </b>",
"     2000 mg every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage of 1000 mg every 8 hours results in similar steady-state concentrations as 2000 mg every 12 hours and is more cost effective (Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic dextrose solution: 1 g (50 mL) [products contain sodium ~48 mg (2mEq)/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg, 1 g, 2 g, 10 g, 20 g, 100 g, 300 g [products contain sodium ~48 mg (2mEq)/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F802619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.M.: Inject deep I.M. into large muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V.: Inject direct I.V. over 5 minutes. Infuse intermittent infusion over 30-60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment. However, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F147138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W,LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, alprostadil, amifostine, anidulafungin, atracurium, aztreonam, bivalirudin, calcium gluconate, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gallium nitrate, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), insulin (regular), labetalol, lidocaine, linezolid, magnesium sulfate, melphalan, meperidine, midazolam, milrinone, morphine, multivitamins, nicardipine, ondansetron, oxytocin, palonesetron, pancuronium, propofol, ranitidine, remifentanil, sargramostim, tacrolimus, teniposide, theophylline, thiotepa, vecuronium, vitamin B complex with C, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, caspofungin, idarubicin, pemetrexed, pentamidine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amiodarone, anakinra, cisatracurium, doxapram, hetastarch in NS, hydromorphone, pantoprazole, promethazine, vancomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of respiratory tract, skin, genital, urinary tract, biliary tract, bone and joint infections, and septicemia due to susceptible gram-positive cocci (except",
"     <i>",
"      Enterococcus",
"     </i>",
"     ); some gram-negative bacilli including",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella",
"     </i>",
"     may be susceptible; surgical prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F147130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis against infective endocarditis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F147140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CeFAZolin may be confused with cefoTEtan, cefOXitin, cefprozil, cefTAZidime, cefTRIAXone, cephalexin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, pruritus, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting, abdominal cramps, anorexia, pseudomembranous colitis, oral candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased, hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, neutropenia, leukopenia, thrombocytopenia, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, serum creatinine increased, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Toxic epidermal necrolysis, abdominal pain, cholestasis, superinfection, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prothrombin time prolonged, pancytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefazolin sodium, any component of the formulation, or other cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: CeFAZolin may decrease the protein binding of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: CeFAZolin may decrease the protein binding of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5944549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies. Cefazolin crosses the placenta. Adverse events have not been reported in the fetus following administration of cefazolin prior to caesarean section. Cefazolin is recommended for group B streptococcus prophylaxis in pregnant patients with a nonanaphylactic penicillin allergy. It is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, the pharmacokinetics of cefazolin are altered. The half-life is shorter, the AUC is smaller, and the clearance and volume of distribution are increased.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F147075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of cefazolin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefazolin to nursing women. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CeFAZolin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $1.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 g (1): $10.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 g (1): $29.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 g (1): $126.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 g (1): $360.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $3.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CeFAZolin Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $2.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (CeFAZolin Sodium-Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g 4% (1): $5.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 g 3% (1): $8.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function periodically when used in combination with other nephrotoxic drugs, hepatic function tests, CBC; monitor for signs of anaphylaxis during first dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azolin (IN);",
"     </li>",
"     <li>",
"      Basocef (DE);",
"     </li>",
"     <li>",
"      Biofazolin (PL);",
"     </li>",
"     <li>",
"      Cefa (TW);",
"     </li>",
"     <li>",
"      Cefacidal (EC, LU, PE, ZA);",
"     </li>",
"     <li>",
"      Cefamezin (AR, HR, IL, JP, KP, PT, RU, TH, TR);",
"     </li>",
"     <li>",
"      Cefarad (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Cefazol (ID, TH);",
"     </li>",
"     <li>",
"      Cefazoline Panpharma (FR);",
"     </li>",
"     <li>",
"      Cefazovit (PH);",
"     </li>",
"     <li>",
"      Celmetin (NO);",
"     </li>",
"     <li>",
"      Cezolin (BR, SG);",
"     </li>",
"     <li>",
"      Cizo (PH);",
"     </li>",
"     <li>",
"      Cloviz (PH);",
"     </li>",
"     <li>",
"      Evalin (ID);",
"     </li>",
"     <li>",
"      Fazol (PH);",
"     </li>",
"     <li>",
"      Fazolin (TH);",
"     </li>",
"     <li>",
"      Fonvicol (PH);",
"     </li>",
"     <li>",
"      Ilozef (PH);",
"     </li>",
"     <li>",
"      Izacef (ZA);",
"     </li>",
"     <li>",
"      Karidina (ES);",
"     </li>",
"     <li>",
"      Kefarin (GR);",
"     </li>",
"     <li>",
"      Kefazin (IL);",
"     </li>",
"     <li>",
"      Kefzol (AT, AU, BE, BF, BJ, CH, CI, CN, ET, GB, GH, GM, GN, HN, HR, HU, IE, KE, LR, LU, MA, ML, MR, MU, MW, NE, NG, NL, PK, SC, SD, SL, SN, TN, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Kelin (TW);",
"     </li>",
"     <li>",
"      Kofatol (TW);",
"     </li>",
"     <li>",
"      Oricef (TW);",
"     </li>",
"     <li>",
"      Orizolin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Primacef (PE);",
"     </li>",
"     <li>",
"      Reflin (IN);",
"     </li>",
"     <li>",
"      Saifuning (CL);",
"     </li>",
"     <li>",
"      Stancef (PH);",
"     </li>",
"     <li>",
"      Stazolin (TW);",
"     </li>",
"     <li>",
"      Totacef (EE, HN, HU, IT);",
"     </li>",
"     <li>",
"      Uzolin (TW);",
"     </li>",
"     <li>",
"      Venozol (ID);",
"     </li>",
"     <li>",
"      Vulmizolin (CZ);",
"     </li>",
"     <li>",
"      Zepilen (BG, NZ);",
"     </li>",
"     <li>",
"      Zofadep (PH);",
"     </li>",
"     <li>",
"      Zolecef (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Zolidina (PY, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely into most body tissues and fluids including gallbladder, liver, kidneys, bone, sputum, bile, pleural, and synovial; CSF penetration is poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 74% to 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimally hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 90-150 minutes; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 0.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80% to 100% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ahern JW, Possidente CJ, Hood V, et al, &ldquo;Cefazolin Dosing Protocol for Patients Receiving Long-term Hemodialysis,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2003, 60(2):178-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/12561661/pubmed\" id=\"12561661\" target=\"_blank\">",
"        12561661",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Advisory Statement. Antibiotic Prophylaxis for Dental Patients With Total Joint Replacements. American Dental Association; American Academy of Orthopedic Surgeons,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1997, 128(7):1004-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/9231605/pubmed\" id=\"9231605\" target=\"_blank\">",
"        9231605",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1999, 56(18):1839-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/10511234/pubmed\" id=\"10511234\" target=\"_blank\">",
"        10511234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al.  &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2013, 70(3):195-283.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/23327981/pubmed\" id=\"23327981\" target=\"_blank\">",
"        23327981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratzler DW and Houck PM (for the Surgical Infection Prevention Guidelines Writers Workgroup), &ldquo;Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 38(12):1706-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/15227616 /pubmed\" id=\"15227616 \" target=\"_blank\">",
"        15227616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Prevention of Perinatal Group B Streptococcal Disease, Revised Guidelines from CDC, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-10):1-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/21088663/pubmed\" id=\"21088663\" target=\"_blank\">",
"        21088663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani, and Nightingale CH, &ldquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dajani AS, Taubert KA, Wilson WW, et al, &ldquo;Prevention of Bacterial Endocarditis. Recommendations by the American Heart Association,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(22):1794-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/9178793/pubmed\" id=\"9178793\" target=\"_blank\">",
"        9178793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, &ldquo;Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,&rdquo;",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Donowitz GR and Mandell GL, &ldquo;Beta-Lactam Antibiotics,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(7):419-26 and 318(8):490-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/3277054/pubmed\" id=\"3277054\" target=\"_blank\">",
"        3277054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell JA, Korth-Bradley J, Milisci M, et al, &ldquo;Evaluating Possible Pharmacokinetic Interactions Between Tobramycin, Piperacillin, and a Combination of Piperacillin and Tazobactam in Patients With Various Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2001, 41:979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/11549103/pubmed\" id=\"11549103\" target=\"_blank\">",
"        11549103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards FH, Engelman RM, Houck P, et al, &ldquo;The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part I: Duration,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2006, 81(1):397-404.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/16368422/pubmed\" id=\"16368422\" target=\"_blank\">",
"        16368422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engelman R, Shahian D, Shemin R, et al, &ldquo;The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2007, 83(4):1569-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/17383396/pubmed\" id=\"17383396\" target=\"_blank\">",
"        17383396",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, &ldquo;Inactivation of Aminoglycosides by Penicillins,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuchs PC, Stickel S, Anderson PH, et al, &ldquo;",
"      <i>",
"       In Vitro",
"      </i>",
"      Inactivation of Aminoglycosides by Sulbactam, Other Beta-Lactams, and Sulbactam-Beta-Lactam Combinations,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(1):182-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/2014975/pubmed\" id=\"2014975\" target=\"_blank\">",
"        2014975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gentry LO, Zeluff BJ, and Cooley DA, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery: A Comparison of Cefamandole, Cefuroxime, and Cefazolin,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1988, 46(2):167-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/3401076/pubmed\" id=\"3401076\" target=\"_blank\">",
"        3401076",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gustaferro CA and Steckelberg JM, &ldquo;Cephalosporin Antimicrobial Agents and Related Compounds,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(10):1064-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/1921490/pubmed\" id=\"1921490\" target=\"_blank\">",
"        1921490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Halstenson CE, Wong MO, Herman CS, et al, &ldquo;Effect of Concomitant Administration of Piperacillin on the Dispositions on Isepamicin and Gentamicin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1992, 36(9):1832-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/1416875/pubmed\" id=\"1416875\" target=\"_blank\">",
"        1416875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hitt CM, Patel KB, Nicolau DP, et al, &ldquo;Influence of Piperacillin-Tazobactam on Pharmacokinetics of Gentamicin Given Once Daily,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(23):2704-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/9408514/pubmed\" id=\"9408514\" target=\"_blank\">",
"        9408514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konishi H, Goto M, Nakamoto Y, et al, &ldquo;Tobramycin Inactivation by Carbenicillin, Ticarcillin, and Piperacillin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 23(5):653-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/6223576/pubmed\" id=\"6223576\" target=\"_blank\">",
"        6223576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau A, Lee M, Flascha S, et al, &ldquo;Effect of Piperacillin on Tobramycin Pharmacokinetics in Patients with Normal Renal Function,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1983, 24(4):533-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/6651279/pubmed\" id=\"6651279\" target=\"_blank\">",
"        6651279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall WF and Blair JE, &ldquo;The Cephalosporins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(2):187-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/10069359/pubmed\" id=\"10069359\" target=\"_blank\">",
"        10069359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peterson CD, Lake KD, Arom KV, et al, &ldquo;Antibiotic Prophylaxis in Open-Heart Surgery Patients: Comparison of Cefamandole and Cefuroxime,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(9):728-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/3498617/pubmed\" id=\"3498617\" target=\"_blank\">",
"        3498617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pickering LK, O'Connor DM, Anderson D, et al, &ldquo;Clinical and Pharmacologic Evaluation of Cefazolin in Children,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1973, 128(Suppl):407-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson DC, Cookson TL, and Grisafe JA, &ldquo;Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(12):985-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/3428165/pubmed\" id=\"3428165\" target=\"_blank\">",
"        3428165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russoe ME and Atkins-Thor E, &ldquo;Gentamicin and Ticarcillin in Subjects With End-Stage Renal Disease. Comparison of Two Assay Methods and Evaluation of Inactivation Rate,&rdquo;",
"      <i>",
"       Clin Nephrol",
"      </i>",
"      , 1981, 15(4):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/7237864/pubmed\" id=\"7237864\" target=\"_blank\">",
"        7237864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simon VC, Malerczyk V, Tenschert B, et al, &ldquo;Die Geriatrische Pharmakologie von Cefazolin, Cefradin, und Sulfisomidin,&rdquo;",
"      <i>",
"       Arzneimittelforschung",
"      </i>",
"      , 1976, 26(7):1377-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/1036929/pubmed\" id=\"1036929\" target=\"_blank\">",
"        1036929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      ,  2010, 15;50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/20034345/pubmed\" id=\"20034345\" target=\"_blank\">",
"        20034345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sowinski KM, Mueller BA, Grabe DW, et al, &ldquo;Cefazolin dialytic Clearance by High-Efficiency and High-Flux Hemodialyzers,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2001, 37(4):766-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/11273877/pubmed\" id=\"11273877\" target=\"_blank\">",
"        11273877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thompson MIB, Russo ME, Saxon BJ, et al, &ldquo;Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1982, 21(2):268-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/6462107/pubmed\" id=\"6462107\" target=\"_blank\">",
"        6462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, &ldquo;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Viollier AF, Standiford HC, Drusano GL, et al, &ldquo;Comparative Pharmacokinetics and Serum Bactericidal Activity of Mezlocillin, Ticarcillin and Piperacillin, With and Without Gentamicin,&rdquo;",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1985, 15(5):597-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/4008387/pubmed\" id=\"4008387\" target=\"_blank\">",
"        4008387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walterspiel JN, Feldman S, Van R, et al, &ldquo;Comparative Inactivation of Isepamicin, Amikacin, and Gentamicin by Nine Beta-Lactams and Two Beta-Lactamase Inhibitors, Cilastatin and Heparin,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1991, 35(9):1875-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/1952861/pubmed\" id=\"1952861\" target=\"_blank\">",
"        1952861",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/2/4136/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9214 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4136=[""].join("\n");
var outline_f4_2_4136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16329907\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147133\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147091\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147112\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147092\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147093\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682521\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147051\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802619\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147138\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147070\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147130\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147140\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147131\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147073\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147055\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298985\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147060\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5944549\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147097\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147075\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147076\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323045\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038553\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147054\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147072\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9214\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9214|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/26/32163?source=related_link\">",
"      Cefazolin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=related_link\">",
"      Cefazolin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_2_4137="Nonthyroid surgery in the patient with thyroid disease";
var content_f4_2_4137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonthyroid surgery in the patient with thyroid disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Ellen F Manzullo, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4137/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4137/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/2/4137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid disease is common; the prevalence is higher in women and with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a cross-sectional study of participants in a health fair, the proportion of subjects with an elevated TSH level increased with age and ranged from 4 to 21 percent in women and 3 to 16 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/3\">",
"     3",
"    </a>",
"    ]. These findings suggest that a significant number of patients who are undergoing surgery may have concomitant thyroid disease.",
"   </p>",
"   <p>",
"    On the other hand, patients who are seriously ill often have abnormal thyroid function tests that may or may not be clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/4\">",
"     4",
"    </a>",
"    ]. These patients need to be distinguished from those who have clinically significant thyroid dysfunction.",
"   </p>",
"   <p>",
"    The issues surrounding thyroid disease in patients undergoing nonthyroid surgery are discussed here. A brief review of thyroid function in seriously ill patients is presented first, followed by specific issues in patients with hypothyroidism and hyperthyroidism. It should be noted that most patients who have well compensated thyroid disease do not need special consideration prior to surgery. The majority of the discussion applies to patients who have a newly diagnosed thyroid disorder around the time of surgery.",
"   </p>",
"   <p>",
"    The management of patients with hyperthyroidism undergoing thyroid surgery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Preoperative preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID FUNCTION IN SERIOUSLY ILL OR HOSPITALIZED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of thyroid function in hospitalized or seriously ill patients can be difficult. The majority of hospitalized patients have a low serum T3 concentration; from 15 to 20 percent of hospitalized patients and up to 50 percent of patients in intensive care units have low serum T4 concentrations (low T4 syndrome). The serum TSH concentration may also be low (",
"    <a class=\"graphic graphic_figure graphicRef61095 \" href=\"UTD.htm?41/37/42589\">",
"     figure 1",
"    </a>",
"    ). Abnormalities in the T3 concentration have been noted in patients undergoing elective or emergency surgery, independent of the type of anesthesia.",
"   </p>",
"   <p>",
"    Previously, these patients were thought to be euthyroid and the term &ldquo;euthyroid sick syndrome&rdquo; was used to describe the laboratory abnormalities. The term \"nonthyroidal illness\" is now preferred since experimental data suggest that these patients develop acquired transient central hypothyroidism. However, there is no evidence of benefit and it is potentially harmful to give thyroid hormone to patients with nonthyroidal illness who have low serum T4 or T3 concentrations. In general, thyroid function should not be assessed in seriously ill patients unless there is a strong suspicion of thyroid dysfunction. When thyroid dysfunction is suspected in critically ill patients, measurement of serum TSH alone is not appropriate for the evaluation of thyroid function. Instead, measurement of TSH, total T4, free T4, T3, and sometimes reverse T3 is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H492117\">",
"    <span class=\"h1\">",
"     IS PREOPERATIVE MEASUREMENT OF TSH NECESSARY?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the relatively high prevalence of thyroid disease in the general population, we believe there is no need to screen for thyroid disease during the preoperative medical consultation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if the history and physical examination are suggestive of thyroid disease, it is reasonable to try to make the diagnosis since it can have effects upon perioperative management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with known thyroid disease taking thyroid medication, monitoring of thyroid function on at least an annual basis is part of routine care. Adjustments in dosing are made as needed to maintain euthyroidism. In these patients with well compensated thyroid disease, we and others believe that additional testing prior to surgery is unnecessary, as long as the patient is on a stable dose of medication and euthyroidism was documented within the past three to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HYPOTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism affects many bodily systems that might influence perioperative outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/5\">",
"     5",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The systemic hypometabolism that is associated with hypothyroidism results in a decrease in cardiac output that is mediated by reductions in heart rate and contractility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"       \"Cardiovascular effects of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoventilation occurs because of respiratory muscle weakness and reduced pulmonary responses to hypoxia and hypercapnia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link&amp;anchor=H2#H2\">",
"       \"Respiratory function in thyroid disease\", section on 'Hypothyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased gut motility results in constipation.",
"     </li>",
"     <li>",
"      A variety of metabolic abnormalities can occur in hypothyroidism, including hyponatremia due to a reduction in free water clearance, reversible increases in serum creatinine, and reduced clearance of some drugs (eg, antiepileptics, anticoagulants, hypnotics, and opioids). Reduced clearance of vitamin K-dependent clotting factors, however, results in higher",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      requirements during hypothyroidism, and falling requirements during treatment with thyroid hormone.",
"     </li>",
"     <li>",
"      Patients with hypothyroidism have a decrease in red blood cell mass and a normochromic, normocytic anemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized studies looking at surgical outcomes in hypothyroid versus euthyroid patients.",
"   </p>",
"   <p>",
"    Older case studies in the anesthesia literature reported intraoperative hypotension, cardiovascular collapse, and extreme sensitivity to opioids, sedatives, and anesthesia in undiagnosed patients with hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In some case reports, myxedema coma is described as a rare postoperative complication in patients with unrecognized severe hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. This represents a medical emergency with a high mortality rate. The hallmarks of myxedema coma are decreased mental status and hypothermia, but hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation are often present as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two retrospective cohort studies examined peri- and postsurgical outcomes in moderately hypothyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study investigated anesthetic and surgical outcomes in 59 hypothyroid patients and 59 paired euthyroid controls [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/12\">",
"       12",
"      </a>",
"      ]. There were no differences between the groups in duration of surgery or anesthesia, lowest temperature and blood pressure recorded during surgery, need for vasopressors, time to extubation, fluid and electrolyte imbalances, incidence of arrhythmias, pulmonary and myocardial infarction, sepsis, need for postoperative respiratory assistance, bleeding complications, or time to hospital discharge. There were also no differences in outcomes among subsets of hypothyroidism determined by the level of thyroxine, although there were only seven patients in the group with the lowest serum T4 concentration (less than 1.0",
"      <span class=\"nowrap\">",
"       mcg/dL,",
"      </span>",
"      normal 5.0 to 13.5",
"      <span class=\"nowrap\">",
"       mcg/dL).",
"      </span>",
"      The authors concluded that there was no evidence to justify deferring needed surgery in patients with mild to moderate hypothyroidism and insufficient evidence to make recommendations for patients with severe hypothyroidism.",
"     </li>",
"     <li>",
"      The second study investigated perioperative complications in 40 hypothyroid patients compared with 80 matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/13\">",
"       13",
"      </a>",
"      ]. The hypothyroid patients had more intraoperative hypotension in noncardiac surgery and more heart failure in cardiac surgery. They also had more postoperative gastrointestinal and neuropsychiatric complications and were less likely to mount a fever with infection. However, there were no differences in perioperative blood loss, duration of hospitalization, or the prevalences of perioperative arrhythmia, hypothermia, hyponatremia, delayed anesthetic recovery, abnormal tissue integrity, impaired wound healing, pulmonary complications or death. The majority of patients in this study had mild to moderate hypothyroidism; only two patients were categorized as having severe hypothyroidism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few data on surgical outcomes in subclinical hypothyroid patients. In a prospective study comparing postoperative outcomes (after coronary artery bypass grafting) in patients with known preoperative subclinical hypothyroidism (elevated TSH with normal free T4) and euthyroid patients, there were no significant differences in major adverse cardiovascular events or other outcomes (wound problems, mediastinitis, leg infection, respiratory complications) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar results were reported in a study of outcomes after percutaneous transluminal coronary angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of clinical trial data, the management of patients with recently diagnosed hypothyroidism who require surgery is based upon observational data and clinical experience. One approach to management is to base therapeutic decisions on the severity of hypothyroidism. One problem in making management recommendations is that definitions of mild, moderate, and severe hypothyroidism can be vague, and definitions may differ between experts or studies. A useful definition of severe hypothyroidism includes patients with myxedema coma, with severe clinical symptoms of chronic hypothyroidism such as altered mentation, pericardial effusion, or heart failure, or those with very low levels of total thyroxine (eg, less than 1.0",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    or free thyroxine (eg, less than 0.5",
"    <span class=\"nowrap\">",
"     ng/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/12,16\">",
"     12,16",
"    </a>",
"    ]. All other patients with overt hypothyroidism (elevated serum TSH, low free thyroxine) can be treated as having moderate disease. Subclinical hypothyroidism is defined biochemically as a normal serum free thyroxine (T4) concentration in the presence of an elevated serum thyrotropin (TSH) concentration and this is, by definition, mild disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26596261\">",
"    <span class=\"h3\">",
"     Subclinical hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the studies in patients undergoing CABG and PTCA described above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], we suggest not postponing surgery in patients with subclinical hypothyroidism (elevated serum TSH, normal free T4).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Moderate (overt) hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the retrospective studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], we suggest that patients with moderate overt hypothyroidism undergo urgent or emergent surgery without delay, with the knowledge that minor perioperative complications might develop. On the other hand, it is prudent to postpone surgery until the euthyroid state is restored when hypothyroidism is discovered in a patient being evaluated for elective surgery.",
"   </p>",
"   <p>",
"    When a diagnosis of moderate hypothyroidism is made preoperatively and surgery cannot be postponed, we suggest initiating thyroid hormone replacement therapy as soon as the diagnosis is made. Generally, young patients are started on close to full replacement doses of thyroxine (T4, 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg),",
"    </span>",
"    while elderly patients or patients with cardiopulmonary disease are started on 25 to 50 mcg daily with an increase in dose every two to six weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hypothyroidism\", section on 'Starting dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Severe hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a lack of outcome data to direct the care of severely hypothyroid patients in the perioperative period. Thus, these patients should be considered high risk and surgery should be delayed until hypothyroidism has been treated. If emergency surgery must be performed in a patient with severe hypothyroidism and there is concern about existing or precipitating myxedema coma (",
"    <a class=\"graphic graphic_table graphicRef54836 \" href=\"UTD.htm?0/9/153\">",
"     table 1",
"    </a>",
"    ), patients should be treated with both T3 and T4 to rapidly normalize thyroid function. As an example, T4 is given in a loading dose of 200 to 300 mcg IV followed by 50 mcg daily. T3 is given simultaneously in a dose of 5 to 20 mcg IV followed by 2.5 to 10 mcg every eight hours depending upon the patient's age and coexistent cardiac risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link\">",
"     \"Myxedema coma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, Addison's disease will be present in a patient with primary hypothyroidism due to Hashimoto&rsquo;s thyroiditis. In addition, patients with central (secondary) hypothyroidism may have inadequate pituitary adrenal reserve as euthyroidism is restored. If the status of the pituitary adrenal axis is uncertain and deficiency is considered likely, patients should be given stress doses of steroid until the integrity of the axis is ascertained. If the clinical situation permits, a cosyntropin stimulation test should be performed prior to administering steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\", section on 'ACTH stimulation tests'",
"    </a>",
"    .) Use of an arterial line and Swan-Ganz catheter should be considered if cardiopulmonary disease exists.",
"   </p>",
"   <p>",
"    In the postoperative period, the patient's fluid and electrolyte status, especially the serum sodium, will need to be followed closely. In addition, a high index of suspicion for the development of an ileus, neuropsychiatric symptoms, and an infectious process without the presence of a fever is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12332612\">",
"    <span class=\"h3\">",
"     Suspected hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, assessment of thyroid function in hospitalized or seriously ill patients can be difficult (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Thyroid function in seriously ill or hospitalized patients'",
"    </a>",
"    above). When thyroid dysfunction is suspected in critically ill patients, measurement of serum TSH alone is not appropriate for the evaluation of thyroid function. Instead, measurement of TSH, total T4, free T4, T3, and sometimes reverse T3 is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=see_link\">",
"     \"Thyroid function in nonthyroidal illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most critically ill patients with moderate or severe primary hypothyroidism, serum TSH will be above the normal range in association with a low free T4, and further management is as described above (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Moderate (overt) hypothyroidism'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Severe hypothyroidism'",
"    </a>",
"    above). Patients with severe nonthyroidal illness may have transient central hypothyroidism, and in these patients, it may be difficult to distinguish nonthyroidal illness from true central hypothyroidism, particularly in patients with a history of hypothalamic or pituitary disease. In this setting, nonurgent surgeries should be postponed and clinical status and thyroid function tests (TSH, free T4) should be monitored every four to six weeks. In patients with transient central hypothyroidism due to nonthyroidal illness, thyroid tests should return to normal, whereas the thyroid test abnormalities will persist in patients with true central hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H977108#H977108\">",
"     \"Central hypothyroidism\", section on 'Transient central hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the diagnosis of hypothyroidism is in doubt in a critically ill patient (because of the difficulty assessing thyroid function in this population) and surgery cannot be postponed, we treat with thyroid hormone replacement in the preoperative and perioperative period if there is clinical evidence to suggest a diagnosis of hypothyroidism (eg, bradycardia and hypothermia along with slow mentation, puffy face, a possible personal or strong family history of thyroid disease, or personal history of hypothalamic or pituitary disease or cranial irradiation). In the absence of suspected myxedema coma, repletion should be cautious, beginning with approximately half the expected full replacement dose of thyroxine (0.8",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    for young patients and 25 to 50 mcg daily for the elderly or patients with cardiopulmonary disease). We measure TSH and free T4 after four to six weeks, and further treatment decisions are based upon the results. In a patient with suspected central hypothyroidism, biochemical assessment of the pituitary adrenal axis should be performed, as described above (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Severe hypothyroidism'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cardiovascular surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypothyroidism who are scheduled to undergo cardiovascular interventions or surgery require special consideration. The risk of precipitating or worsening unstable coronary syndromes with thyroid hormones conflicts with the concern that untreated hypothyroidism might worsen heart failure or hypotension in the cardiac surgical patient. Retrospective and prospective studies of cardiac patients found no adverse outcomes in cardiac patients with mild to moderate hypothyroidism who had cardiac surgery or catheterization without thyroid replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In a prospective study comparing postoperative outcomes in patients with known preoperative subclinical hypothyroidism (elevated TSH with normal free T4) and euthyroid patients, there were no significant differences in major adverse cardiovascular events or other outcomes (wound problems, mediastinitis, leg infection, respiratory complications) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angina is not an absolute contraindication to thyroid hormone replacement if the patient has symptomatic hypothyroidism. Some patients will experience improvement in their angina symptoms with therapy. A 1961 report remains the largest and best study of the effects of beginning thyroid hormone on chest pain in patients with hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/9\">",
"     9",
"    </a>",
"    ]. Among 1503 hypothyroid patients, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fifty-five had angina before thyroid hormone replacement therapy. During therapy, 21 improved, 25 had no change, and nine had more angina.",
"     </li>",
"     <li>",
"      Thirty-five patients developed new angina during therapy, six during the first month, six during the first year, and 23 after one year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, angina may improve and it does not often first appear during T4 replacement therapy. Presently, most patients with angina have coronary artery revascularization first and T4 is prescribed afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/5\">",
"     5",
"    </a>",
"    ]. In most patients, angina has resolved after revascularization before T4 has been prescribed. We agree with this approach. In patients with angina treated medically, the dose of T4 should begin with 25",
"    <span class=\"nowrap\">",
"     micrograms/day",
"    </span>",
"    and is increased 25 micrograms every two to six weeks, depending upon response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of hypothyroidism\", section on 'Older patients or those with coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Postoperative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving chronic T4 therapy who undergo surgery and are unable to eat for several days do not need to be given T4 parenterally. If oral intake cannot be resumed in five to seven days, then T4 should be given intravenously or intramuscularly. The dose should be approximately 70 to 80 percent of the patient's usual oral dose because that is about the fraction of oral T4 that is absorbed. We typically give 80 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of hypothyroidism\", section on 'Surgical patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with hypothyroidism, hyperthyroidism affects many bodily systems that might influence perioperative outcome (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hyperthyroidism have an increase in cardiac output, due both to increased peripheral oxygen needs and increased cardiac contractility. Heart rate is increased, pulse pressure is widened, and peripheral vascular resistance is decreased. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"       \"Cardiovascular effects of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial fibrillation occurs in about 8 percent of patients with hyperthyroidism and is more common in elderly patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Even subclinical hyperthyroidism is associated with increased rates of atrial ectopy and a threefold increased risk of atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H9#H9\">",
"       \"Subclinical hyperthyroidism\", section on 'Atrial fibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dyspnea may occur for a variety of reasons, including increased oxygen consumption and CO2 production, respiratory weakness, and decreased lung volume. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link&amp;anchor=H9#H9\">",
"       \"Respiratory function in thyroid disease\", section on 'Hyperthyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight loss is due primarily to increased calorigenesis, and secondarily to increased gut motility and the associated hyperdefecation and malabsorption; these changes can cause the patient to be malnourished.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published studies evaluating the risks of nonthyroid surgery in hyperthyroid patients. In patients with untreated or poorly controlled hyperthyroidism, an acute event such as surgery can precipitate thyroid storm, a potentially life-threatening condition (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Thyroid storm'",
"    </a>",
"    below). Thus, all elective surgeries should be postponed in patients with newly discovered overt hyperthyroidism until the patient has achieved adequate control of their thyroid condition (usually three to eight weeks). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"     \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our experience, patients with subclinical hyperthyroidism (low TSH, normal free T4 and T3) can typically proceed with elective surgeries. Unless contraindicated, we typically administer a beta blocker preoperatively to older patients (&gt;50 years) or younger patients with cardiovascular disease, and taper after recovery. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H592559\">",
"    <span class=\"h3\">",
"     Preoperative preparation for urgent surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are instances when patients with overt hyperthyroidism require urgent or emergent surgery. Such patients require preoperative preparation, typically with beta blockers and thionamides. If hyperthyroidism is severe and the need for surgery is urgent, we also add",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    solution (SSKI, one to five drops three times daily) one hour",
"    <strong>",
"     after",
"    </strong>",
"    thionamides. Extreme caution is necessary before administering SSKI to a patient with known or suspected toxic nodular goiter since iodine, in the absence of a thionamide to block organification, may exacerbate the hyperthyroidism. Patients with toxic nodular goiter who are intolerant or unable to take thionamides should be pretreated with beta blockers alone, whereas patients with Graves' hyperthyroidism who are allergic to or are intolerant of thionamides can be treated with the combination of beta blockers and iodine. In patients who are allergic to or do not tolerate antithyroid drugs, urgent thyroidectomy may rarely be required prior to nonthyroidal surgery.",
"   </p>",
"   <p>",
"    In the preoperative period, the hyperthyroid patient requiring urgent surgery should be evaluated for possible cardiopulmonary disease and all efforts should be focused upon optimizing the patient's condition. Use of an arterial line and Swan-Ganz catheter should be considered if cardiopulmonary disease exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the benefits of beta blocker administration to hyperthyroid patients undergoing nonthyroid surgery. The literature on hyperthyroid patients undergoing thyroid surgery suggests that beta blockers administered preoperatively effectively control the clinical manifestations of hyperthyroidism and are as effective as a thionamide for preoperative preparation of the hyperthyroid patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As an example, in a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    in 30 patients with newly diagnosed and untreated hyperthyroidism undergoing thyroid surgery, there was no difference in anesthesiologic or cardiovascular complications during surgery or in postoperative complications post-surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/20\">",
"     20",
"    </a>",
"    ]. The results of this trial suggest that serious perioperative complications are low in patients undergoing thyroid surgery who are treated preoperatively with beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, in the absence of contraindications, we administer a beta blocker preoperatively to patients with overt hyperthyroidism undergoing nonthyroid surgery. The longer acting beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) are preferred in patients who are candidates for therapy because an oral dose taken one hour before surgery will usually maintain adequate beta blockade until the patient is able to take oral medications postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/23\">",
"     23",
"    </a>",
"    ]. We typically start with atenolol 25 to 50 mg daily and increase the dose as needed to maintain the pulse rate below 80",
"    <span class=\"nowrap\">",
"     beats/minute;",
"    </span>",
"    up to 200 mg daily may be needed for the symptomatic treatment of hyperthyroidism and control of tachycardia. Beta blockers should be continued until the patient's thyroid disease is under control. Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (0.5 to 1 mg over 10 minutes followed by 1 to 2 mg over 10 minutes every few hours) can be used to control fever, hypertension, and tachycardia intraoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with relative contraindications to beta blockade may better tolerate beta 1-selective agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , although even these drugs cannot be considered completely safe in patients with asthma or chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2021?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hypertension in asthma and COPD\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium channel blockers can also be used for rate control in patients in whom beta blockers are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Thionamides and iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thionamides block de novo thyroid hormone synthesis but have no effect upon the release of preformed hormone from the thyroid gland, and will therefore not have a significant effect on thyroid hormone levels over only a few preoperative days. Nevertheless, once the diagnosis of hyperthyroidism associated with an elevated radioiodine uptake is established, thionamides should be initiated with the aim of controlling hyperthyroidism in the postoperative period.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     Methimazole",
"    </a>",
"    (10 mg two to three times daily or 20 to 30 mg once daily) is usually preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU), except during pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. PTU (100 to 150 mg every six to eight hours) is also preferred by some clinicians for the initial treatment of thyroid storm since it reduces T4-to-T3 conversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link&amp;anchor=H4#H4\">",
"     \"Thyroid storm\", section on 'Thionamides'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While thionamides alone are sufficient to achieve euthyroidism in approximately three to eight weeks, we suggest adding iodine (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    solution, SSKI, one to five drops three times daily) at least one hour",
"    <strong>",
"     after",
"    </strong>",
"    thionamides are administered, if hyperthyroidism is severe and the need for surgery is urgent. Iodine blocks release of T4 and T3 from the gland and thereby shortens the time to achieving a euthyroid state. This effect, however, may be transient, and the use of iodine to block release of hormone beyond 10 days is not generally recommended; it can be started 10 days preoperatively for urgent procedures that are scheduled more than 10 days in the future, but which cannot be delayed until the patient is chemically euthyroid following a thionamide. Iopanoic acid (which is also rich in iodine) blocks both release of T4 and T3 from the gland and T4-to-T3 conversion, but is not currently available in much of the world. Where available, iopanoic acid 500 mg daily added to a thionamide will reduce thyroid hormone levels more rapidly than other regimens. If iopanoic acid is available, the benefit of PTU over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    is moot (iopanoic acid is a more potent inhibitor of T4-to-T3 conversion) and methimazole should be used because of its longer duration of action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iodine and iopanoic acid should not be used as primary therapy (without thionamides) in patients with toxic nodular goiter because the iodine load can exacerbate the hyperthyroidism. Thionamide therapy should therefore be started first and continued without interruption. If the patient is unable to continue oral thionamides and has been loaded with iodine, hyperthyroidism may worsen. Patients who cannot take oral medications postoperatively will need rectal administration of thionamides, which should be ordered well in advance from the pharmacy (",
"    <a class=\"graphic graphic_table graphicRef79245 \" href=\"UTD.htm?16/13/16604\">",
"     table 2",
"    </a>",
"    ). Thus, iodine after thionamide administration should be used cautiously in patients with toxic nodular goiter and should not be used at all if the patient will be unable to continue oral or rectal thionamides. Patients with toxic nodular goiter who are intolerant or unable to take thionamides should be pretreated with beta blockers alone.",
"   </p>",
"   <p>",
"    In contrast, in patients with Graves' disease, exogenous iodine is unlikely to exacerbate hyperthyroidism by acting as substrate. Thus, for patients with Graves&rsquo; hyperthyroidism who are allergic to or are intolerant of thionamides, the combination of beta blockers and iodine can be used for preoperative preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Intraoperative and postoperative concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the operative and postoperative period, particular attention should be focused upon the patient's cardiac status and the patient should be monitored for the possible development of arrhythmias, cardiac ischemia, and congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4137/abstract/26\">",
"     26",
"    </a>",
"    ]. Hyperthyroid patients are also at increased risk of prolonged intubation due to increased basal oxygen consumption and respiratory muscle weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Thyroid storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism are at risk for developing thyroid storm, a condition that usually occurs during surgery or in the first 18 hours after the procedure. The mortality rate for patients with thyroid storm can be as high as 40 percent. Clinical features of thyroid storm include (",
"    <a class=\"graphic graphic_table graphicRef60908 \" href=\"UTD.htm?34/24/35213\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular symptoms such as tachycardia to rates that can exceed 140",
"      <span class=\"nowrap\">",
"       beats/minute,",
"      </span>",
"      along with congestive heart failure in many patients",
"     </li>",
"     <li>",
"      Hyperpyrexia to 104 to 106&ordm;F",
"     </li>",
"     <li>",
"      Agitation, delirium, psychosis, stupor, or coma",
"     </li>",
"     <li>",
"      Severe nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea, and hepatic failure with jaundice",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic options for thyroid storm are essentially the same as those for uncomplicated hyperthyroidism, except that the drugs are given in higher doses and more frequently. In addition, infection needs to be identified and treated, and hyperpyrexia should be aggressively corrected.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which can increase serum free T4 and T3 concentrations by interfering with protein binding. Cooling blankets can be used if hyperthermia develops during surgery. Full support of the patient in an intensive care unit is essential, since the mortality rate of thyroid storm is substantial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link&amp;anchor=H2#H2\">",
"     \"Thyroid storm\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491880\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite the relatively high prevalence of thyroid disease in the general population, we believe there is no need to screen for thyroid disease during the preoperative medical consultation. However, if the history and physical examination are suggestive of thyroid disease, it is reasonable to try to make the diagnosis since it can have effects upon perioperative management. (See",
"      <a class=\"local\" href=\"#H492117\">",
"       'Is preoperative measurement of TSH necessary?'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"       \"Preoperative medical evaluation of the healthy patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with subclinical hypothyroidism (elevated serum TSH, normal free T4) do not require treatment before urgent or emergent surgery. In our experience, patients with subclinical hypothyroidism can typically proceed with elective surgeries. (See",
"      <a class=\"local\" href=\"#H26596261\">",
"       'Subclinical hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate (overt) hypothyroidism who require",
"      <strong>",
"       urgent",
"      </strong>",
"      or",
"      <strong>",
"       emergent",
"      </strong>",
"      surgery, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      postponing surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), with the knowledge that minor perioperative complications might develop. Such patients should be treated with thyroid hormone as soon as the diagnosis is made. Generally, young patients are started on close to full replacement doses of thyroxine (1.6",
"      <span class=\"nowrap\">",
"       mcg/kg),",
"      </span>",
"      while elderly patients or patients with cardiopulmonary disease are started on 25 to 50 mcg daily with an increase in dose every two to six weeks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Moderate (overt) hypothyroidism'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      On the other hand, when moderate hypothyroidism is discovered in a patient being evaluated for elective surgery, we suggest postponing",
"      <strong>",
"      </strong>",
"      surgery until the euthyroid state is restored (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with severe hypothyroidism (myxedema coma, severe clinical symptoms of chronic hypothyroidism such as altered mentation, pericardial effusion, or heart failure, or very low levels of total thyroxine [eg, less than 1.0",
"      <span class=\"nowrap\">",
"       mcg/dL])",
"      </span>",
"      or free T4 (eg, less than 0.5",
"      <span class=\"nowrap\">",
"       ng/dL),",
"      </span>",
"      surgery should be delayed until hypothyroidism has been treated. If emergency surgery is required, the severely hypothyroid patient should be treated as soon as the diagnosis is made. If emergency surgery must be performed in a patient with myxedema coma, we suggest treatment with both T3 and T4, rather than T4 alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Severe hypothyroidism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link&amp;anchor=H11#H11\">",
"       \"Myxedema coma\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with secondary hypothyroidism may have associated hypopituitarism and secondary adrenal insufficiency. In addition, patients with autoimmune-mediated primary hypothyroidism may have concomitant primary adrenal insufficiency. If the status of the pituitary adrenal axis is uncertain and deficiency is considered likely in a patient with severe hypothyroidism requiring emergent surgery, patients should be given stress doses of steroid until the integrity of the axis is ascertained. If the clinical situation permits, a cosyntropin stimulation test should be performed prior to administering steroids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Severe hypothyroidism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=see_link&amp;anchor=H11#H11\">",
"       \"Myxedema coma\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the diagnosis of hypothyroidism is in doubt in a critically ill patient (because of the difficulty assessing thyroid function in this population) and surgery cannot be postponed, we treat with thyroid hormone replacement in the preoperative and perioperative period if there is clinical evidence to suggest a diagnosis of hypothyroidism (eg, bradycardia and hypothermia along with slow mentation, puffy face, a possible personal or strong family history of thyroid disease, or personal history of hypothalamic or pituitary disease or cranial irradiation). In the absence of suspected myxedema coma, repletion should be cautious, beginning with approximately half the expected full replacement dose of thyroxine (0.8",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      for young patients and 25 to 50 mcg daily for the elderly or patients with cardiopulmonary disease). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid function in seriously ill or hospitalized patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12332612\">",
"       'Suspected hypothyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with untreated or poorly controlled overt hyperthyroidism, an acute event such as surgery can precipitate thyroid storm, a potentially life-threatening condition. Thus, we suggest postponing surgery in patients with newly discovered overt hyperthyroidism until the patient has achieved adequate control of their thyroid condition (usually three to eight weeks) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"       \"Treatment of Graves' hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=see_link\">",
"       \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For overtly hyperthyroid patients in whom surgery cannot be postponed, preoperative treatment of hyperthyroidism should be initiated as soon as possible. (See",
"      <a class=\"local\" href=\"#H592559\">",
"       'Preoperative preparation for urgent surgery'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the absence of contraindications, we recommend administering a beta blocker (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ), typically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg daily with the dose increased as needed to maintain the pulse rate below 80",
"      <span class=\"nowrap\">",
"       beats/minute.",
"      </span>",
"      Beta blockers should be continued until the patient's thyroid disease is under control. Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (0.5 to 1 mg over 10 minutes followed by 1 to 2 mg over 10 minutes every few hours) can be used to control fever, hypertension, and tachycardia intraoperatively. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition, once the diagnosis of hyperthyroidism due to Graves&rsquo; disease or nodular hyperthyroidism is established, we suggest starting a thionamide (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), with the aim of controlling hyperthyroidism in the postoperative period.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"       Methimazole",
"      </a>",
"      (10 mg two to three times daily or 20 to 30 mg once daily) is usually preferred to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      (PTU), except during the first trimester of pregnancy, because of its longer duration of action (allowing for single daily dosing) and a lesser degree of toxicity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thionamides and iodine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If hyperthyroidism is severe and the need for surgery is urgent, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"       potassium iodide",
"      </a>",
"      solution (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (SSKI, one to five drops three times daily) one hour",
"      <strong>",
"       after",
"      </strong>",
"      thionamides. For patients who are unable to continue oral thionamides, thionamides can be prepared for rectal administration (",
"      <a class=\"graphic graphic_table graphicRef79245 \" href=\"UTD.htm?16/13/16604\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thionamides and iodine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with Graves&rsquo; hyperthyroidism who are allergic to or are intolerant of thionamides, the combination of beta blockers and iodine can be used for preoperative preparation. Patients with toxic nodular goiter who are allergic to or are intolerant of thionamides should be treated with beta blockers alone, as iodine may worsen hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thionamides and iodine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our experience, patients with subclinical hyperthyroidism (low TSH, normal free T4 and T3) can typically proceed with elective surgeries. Unless contraindicated, we administer a beta blocker preoperatively to older patients (&gt;50 years) or younger patients with cardiovascular disease, and taper after recovery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441834\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to acknowledge Dr. Gail A Welsh, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/1\">",
"      Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence, incidence, and regression of thyroid diseases in adolescents and young adults. Am J Med 1991; 91:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/2\">",
"      Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/3\">",
"      Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/4\">",
"      Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/5\">",
"      Stathatos N, Wartofsky L. Perioperative management of patients with hypothyroidism. Endocrinol Metab Clin North Am 2003; 32:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/6\">",
"      Abbott TR. Anaesthesia in untreated myxoedema. Report of two cases. Br J Anaesth 1967; 39:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/7\">",
"      Kim JM, Hackman L. Anesthesia for untreated hypothyroidism: report of three cases. Anesth Analg 1977; 56:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/8\">",
"      Appoo JJ, Morin JF. Severe cerebral and cardiac dysfunction associated with thyroid decompensation after cardiac operations. J Thorac Cardiovasc Surg 1997; 114:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/9\">",
"      CATZ B, RUSSELL S. Myxedema, shock and coma. Seven survival cases. Arch Intern Med 1961; 108:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/10\">",
"      HOLVEY DN, GOODNER CJ, NICOLOFF JT, DOWLING JT. TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE. Arch Intern Med 1964; 113:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/11\">",
"      Ragaller M, Quintel M, Bender HJ, Albrecht DM. [Myxedema coma as a rare postoperative complication]. Anaesthesist 1993; 42:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/12\">",
"      Weinberg AD, Brennan MD, Gorman CA, et al. Outcome of anesthesia and surgery in hypothyroid patients. Arch Intern Med 1983; 143:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/13\">",
"      Ladenson PW, Levin AA, Ridgway EC, Daniels GH. Complications of surgery in hypothyroid patients. Am J Med 1984; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/14\">",
"      Park YJ, Yoon JW, Kim KI, et al. Subclinical hypothyroidism might increase the risk of transient atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2009; 87:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/15\">",
"      Sherman SI, Ladenson PW. Percutaneous transluminal coronary angioplasty in hypothyroidism. Am J Med 1991; 90:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/16\">",
"      Bennett-Guerrero E, Kramer DC, Schwinn DA. Effect of chronic and acute thyroid hormone reduction on perioperative outcome. Anesth Analg 1997; 85:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/17\">",
"      Drucker DJ, Burrow GN. Cardiovascular surgery in the hypothyroid patient. Arch Intern Med 1985; 145:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/18\">",
"      Myerowitz PD, Kamienski RW, Swanson DK, et al. Diagnosis and management of the hypothyroid patient with chest pain. J Thorac Cardiovasc Surg 1983; 86:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/19\">",
"      Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/20\">",
"      Adlerberth A, Stenstr&ouml;m G, Hasselgren PO. The selective beta 1-blocking agent metoprolol compared with antithyroid drug and thyroxine as preoperative treatment of patients with hyperthyroidism. Results from a prospective, randomized study. Ann Surg 1987; 205:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/21\">",
"      Vickers P, Garg KM, Arya R, et al. The role of selective beta 1-blocker in the preoperative preparation of thyrotoxicosis: a comparative study with propranolol. Int Surg 1990; 75:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/22\">",
"      Feek CM, Sawers JS, Irvine WJ, et al. Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med 1980; 302:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/23\">",
"      Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/24\">",
"      Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/25\">",
"      Das G, Krieger M. Treatment of thyrotoxic storm with intravenous administration of propranolol. Ann Intern Med 1969; 70:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4137/abstract/26\">",
"      Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7858 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4137=[""].join("\n");
var outline_f4_2_4137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H491880\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID FUNCTION IN SERIOUSLY ILL OR HOSPITALIZED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H492117\">",
"      IS PREOPERATIVE MEASUREMENT OF TSH NECESSARY?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HYPOTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26596261\">",
"      - Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Moderate (overt) hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Severe hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12332612\">",
"      - Suspected hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cardiovascular surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Postoperative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H592559\">",
"      - Preoperative preparation for urgent surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Thionamides and iodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Intraoperative and postoperative concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H491880\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H441834\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7858\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7858|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/37/42589\" title=\"figure 1\">",
"      Thyroid function sick patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7858|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/153\" title=\"table 1\">",
"      Features of myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/13/16604\" title=\"table 2\">",
"      Preparation of rectal formulations of thionamides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/24/35213\" title=\"table 3\">",
"      Criteria for thyroid storm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8566?source=related_link\">",
"      Myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=related_link\">",
"      Respiratory function in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44663?source=related_link\">",
"      Thyroid function in nonthyroidal illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/62/2021?source=related_link\">",
"      Treatment of hypertension in asthma and COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_2_4138="Ocular cicatricial pemphigoid";
var content_f4_2_4138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ocular cicatricial pemphigoid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4138/contributors\">",
"     Stephen Foster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4138/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/2/4138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/2/4138/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/2/4138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2913441\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane pemphigoid is a heterogeneous group of chronic inflammatory blistering diseases that affect oral, ocular, pharyngeal, laryngeal, genital, or anal mucosa. The characteristic pathological feature that unites these disorders is the presence of linear deposits of IgG, IgA, or C3 in the epithelial basement membrane zone. The term ocular cicatricial pemphigoid (OCP) refers to mucous membrane pemphigoid that clinically presents as a chronic cicatrizing (scarring) conjunctivitis. Involvement of other mucosal sites and nonmucosal skin may also occur in OCP.",
"   </p>",
"   <p>",
"    Left untreated, OCP eventually results in severe conjunctival scarring and visual loss. Thus, early diagnosis and prompt initiation of therapy are essential for optimal management. The treatment of OCP involves the suppression of conjunctival inflammation via the use of systemic immunomodulatory drugs. Conscientious ocular care to minimize the secondary consequences of chronic inflammation also is important.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, diagnosis, and treatment of OCP will be reviewed here. Other forms of pemphigoid are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913448\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of OCP is estimated to be between 1 in 8000 and 1 in 46,000 ophthalmic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. No geographical or racial predilection has been detected.",
"   </p>",
"   <p>",
"    OCP is primarily a disease of older adults, with an average age of diagnosis between the ages of 60 and 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. However, due to the nonspecific conjunctival inflammation that characterizes early stage OCP, in some patients the disease may be present for years prior to recognition of the diagnosis.",
"   </p>",
"   <p>",
"    OCP appears to have a predilection for women. The female to male ratio is estimated to be between 1.5:1 and 3:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. The occurrence of OCP in children is rare; as of 2011, less than 20 pediatric patients have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913490\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chronic, cicatrizing conjunctivitis of OCP is a manifestation of a systemic autoimmune disorder characterized by the aberrant production of antibodies that recognize normal components of the mucosal epithelial basement membrane zone. As in other forms of pemphigoid, the interaction of these antibodies with their target antigens is believed to precipitate the clinical manifestations of OCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several components of the basement membrane zone have been identified as potential antigenic targets in cicatricial pemphigoid, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &beta;4 peptide of &alpha;6&beta;4 integrin (a transmembrane anchoring protein that links basal cell hemidesmosomes to the underlying basement membrane zone) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/9-11\">",
"       9-11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Laminin 5 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bullous pemphigoid antigen 2 (BP 180) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Unspecified 168 kilodalton and 45 kilodalton antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, in OCP, the 205 kilodalton &beta;4 peptide of &alpha;6&beta;4 integrin appears to be a frequent target antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/9,10,18\">",
"     9,10,18",
"    </a>",
"    ]. An epitope in the large cytoplasmic domain of the &beta;4 peptide has the strongest binding affinity for autoantibodies in sera from patients with OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to pemphigoid involving cutaneous surfaces, which typically manifests as disassociation of the epidermis and dermis (eg, blistering skin in bullous pemphigoid), in OCP the immune-mediated process manifests as a chronic, scarring conjunctivitis. The following sequence of events may contribute to the development of the clinical findings in OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autoantibody binding in the basement membrane zone stimulates an inflammatory cascade that involves the secretion of cytokines and the recruitment of inflammatory cells",
"     </li>",
"     <li>",
"      Recruited inflammatory cells sustain inflammation through the secretion of additional proinflammatory cytokines",
"     </li>",
"     <li>",
"      The release of profibrotic cytokines by inflammatory cells, such as transforming growth factor (TGF)-beta and interferon (IFN)-gamma contributes to the development of scarring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inciting factors for OCP are not definitively known. It is suspected that a combination of genetic susceptibility and environmental insults contributes to the production of pathogenic autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. The HLA DQW7 (HLA DQ&beta;*0301) allele has been identified as a potential risk factor for OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and medications or microbial organisms may be relevant environmental contributors.",
"   </p>",
"   <p>",
"    In a small subset of patients with OCP, a potential contributing factor is detected. Cases in which topical ophthalmic medications or systemic practolol have been linked to the development of OCP (also known as pseudopemphigoid or pseudo-OCP) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/24-31\">",
"     24-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, intense conjunctival inflammation has been proposed as a potential inciting factor for OCP via a process referred to as epitope spreading [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ]. The epitope spreading theory describes the immune detection of normal host antigens during tissue inflammation and the subsequent mounting of an aberrant autoimmune response against those antigens. The development of OCP following Stevens-Johnson syndrome has been attributed to this theory [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/33\">",
"     33",
"    </a>",
"    ]. Additional studies are necessary to determine whether this is a legitimate pathway for the induction of OCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913497\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of OCP vary according to the stage of the disease. Extraocular involvement may or may not be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378742\">",
"    <span class=\"h2\">",
"     Ocular findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of initial symptoms, OCP may present with unilateral eye involvement. However, bilateral disease usually develops within two to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5,34\">",
"     5,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early disease may present only with signs of a chronic or relapsing conjunctivitis, with symptoms such as tearing, irritation, burning, or mucus drainage (",
"    <a class=\"graphic graphic_picture graphicRef65724 \" href=\"UTD.htm?29/16/29955\">",
"     picture 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/35\">",
"     35",
"    </a>",
"    ]. Frank vesicles on the conjunctiva are infrequently detected.",
"   </p>",
"   <p>",
"    As the disease progresses, fibrosis ensues, resulting in conjunctival shrinkage (",
"    <a class=\"graphic graphic_picture graphicRef78279 \" href=\"UTD.htm?4/35/4659\">",
"     picture 1B",
"    </a>",
"    ). Symblephara (fibrotic adhesions between the bulbar and palpebral conjunctivae), which typically begin in the inferior fornix, can become so severe that they impair eye movement (",
"    <a class=\"graphic graphic_picture graphicRef54207 \" href=\"UTD.htm?31/12/31937\">",
"     picture 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. As a consequence of scarring, some patients also may develop lagophthalmos (loss of the ability to completely close the eye).",
"   </p>",
"   <p>",
"    Moreover, involvement of the eyelid margin can lead to ankyloblepharon (fusion of the lid margins of the upper and lower eyelids). Inflammation and scarring in this area may also disrupt the orientation of eyelash follicles, resulting in trichiasis (inward growth of the eyelashes) or distichiasis (a duplicate row of eyelashes in which one or both grow inward against the eye) (",
"    <a class=\"graphic graphic_picture graphicRef75647 \" href=\"UTD.htm?24/56/25477\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Visual impairment eventually occurs if OCP is not adequately controlled. Xerophthalmia leading to corneal keratinization occurs as a consequence of the destruction of the ducts of the lacrimal glands, the elimination of goblet cells which produce the mucus component of the tear film, or the development of lagophthalmos. Additionally, direct trauma to the corneal surface in the setting of entropion or trichiasis contributes to corneal keratinization, neovascularization, and scarring (",
"    <a class=\"graphic graphic_picture graphicRef66981 \" href=\"UTD.htm?22/61/23508\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378785\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staging systems have been developed to assist in the assessment of disease severity and treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5,36,37\">",
"     5,36,37",
"    </a>",
"    ]. In 1986, we proposed the following categories for the classification of OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage I",
"      </strong>",
"      &ndash; Chronic conjunctivitis with subepithelial fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef65724 \" href=\"UTD.htm?29/16/29955\">",
"       picture 1A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Stage II",
"      </strong>",
"      &ndash; Shortening of the inferior fornix (",
"      <a class=\"graphic graphic_picture graphicRef78279 \" href=\"UTD.htm?4/35/4659\">",
"       picture 1B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Stage III",
"      </strong>",
"      &ndash; Symblepharon (",
"      <a class=\"graphic graphic_picture graphicRef54207 \" href=\"UTD.htm?31/12/31937\">",
"       picture 1C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Stage IV",
"      </strong>",
"      &ndash; End stage disease manifesting as ankyloblepharon, severe sicca syndrome, severe ocular surface keratinization (",
"      <a class=\"graphic graphic_picture graphicRef66981 \" href=\"UTD.htm?22/61/23508\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the modified version of this staging system, stages II and III are further subdivided in to four groups that describe the degree of involvement (a = 0 to 25 percent, b = 25 to 50 percent, c = 50 to 75 percent, and d = 75 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/36\">",
"     36",
"    </a>",
"    ]. For stage II, the designation describes the percent loss of the inferior fornix depth II, while in stage III this describes the percentage of horizontal involvement by symblephara. The number of symblephara is also noted. For example, a patient with stage IIcIIIb(2) would have 50 to 75 percent loss of the inferior fornix and 25 to 50 percent involvement by two symblephera.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378771\">",
"    <span class=\"h2\">",
"     Extraocular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant oral disease is common in patients with OCP. Oral lesions are estimated to occur in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ]. Erosive gingivitis is the most common oral manifestation, but involvement manifesting as erosions or vesicles may also occur on the buccal mucosa, palate, alveolar ridge, tongue, and lip [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/35\">",
"     35",
"    </a>",
"    ]. Other mucosal sites affected less frequently than the oral cavity include the pharynx, nose, larynx, genitalia, anus, and esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to oral disease, a smaller subset of patients with OCP has involvement of nonmucosal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study from an ophthalmologic practice, 16 percent of patients had skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ]. Such patients most frequently present with inflammatory bullae and erosions on the head, neck, and upper trunk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913529\">",
"    <span class=\"h1\">",
"     ESTABLISHING THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The systemic immunomodulatory therapies required for the treatment of OCP are associated with a number of potential severe adverse effects. This, and the fact that the approach to treatment differs significantly from the therapeutic approach for some of the other disorders that clinically resemble OCP, strongly favor confirmation of the diagnosis whenever feasible (see",
"    <a class=\"local\" href=\"#H378908\">",
"     'Differential diagnosis'",
"    </a>",
"    below). A perilesional tissue biopsy with immunohistochemical studies is a valuable tool for confirming the diagnosis in patients with clinical findings suggestive of OCP. However, clinicians must remain cognizant that inconclusive or negative results do not rule out the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2828114\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have extraocular lesions, such as skin or other mucosal lesions, the tissue biopsy for diagnosis should first be attempted in these more easily accessible sites [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32,34\">",
"     32,34",
"    </a>",
"    ]. Conjunctival biopsies are generally performed in patients with active disease limited to the ocular mucosa or in patients in whom the disease is strongly suspected despite negative or inconclusive results from extraocular biopsies.",
"   </p>",
"   <p>",
"    Biopsies should always be performed on perilesional tissue (tissue adjacent to inflamed tissue), rather than within a mucosal or skin lesion, since false negative results may occur with the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ]. Conjunctival biopsies may be obtained from a variety of sites; we typically biopsy the bulbar conjunctiva.",
"   </p>",
"   <p>",
"    Negative or inconclusive results can occur due to poor biopsy technique or poor handling of the specimen. Conjunctival biopsies should only be performed by ophthalmologists, and only experienced laboratory technicians should process conjunctival tissue. Disease exacerbation and the induction of scarring are potential risks of conjunctival biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2198362\">",
"    <span class=\"h3\">",
"     Hematoxylin and eosin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings in specimens stained with hematoxylin and eosin (H&amp;E) are nonspecific. Examination typically demonstrates an inflammatory infiltrate of variable intensity composed of neutrophils, macrophages, plasma cells, lymphocytes, and Langerhans cells (",
"    <a class=\"graphic graphic_picture graphicRef55683 \" href=\"UTD.htm?13/41/13972\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ]. Squamous metaplasia may also be present (",
"    <a class=\"graphic graphic_picture graphicRef68490 \" href=\"UTD.htm?33/37/34399\">",
"     picture 5",
"    </a>",
"    ). The performance of additional histopathological stains facilitates the identification of other common features, such as decreased goblet cells (PAS stain) (",
"    <a class=\"graphic graphic_picture graphicRef61302 \" href=\"UTD.htm?25/51/26422\">",
"     picture 6",
"    </a>",
"    ) and increased mast cells (Giemsa stain) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378882\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence should be performed on all conjunctival biopsy specimens. Linear deposition of IgG, IgA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C3 is the characteristic finding (",
"    <a class=\"graphic graphic_picture graphicRef74474 \" href=\"UTD.htm?27/2/27683\">",
"     picture 7",
"    </a>",
"    ). However, because the diagnostic sensitivity of direct immunofluorescence is only around 50 percent, a negative test does not rule out the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utilization of an immunoperoxidase assay may improve the likelihood of diagnosis, and the technique should be performed if immunofluorescence is negative in a patient with clinical features strongly suggestive of OCP (",
"    <a class=\"graphic graphic_picture graphicRef82652 \" href=\"UTD.htm?3/49/3856\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ]. In a retrospective study of 166 patients with suspected OCP, performance of an immunoperoxidase avidin-biotin-complex assay on specimens that yielded negative or inconclusive immunofluorescence results was associated with the detection of additional diagnoses of OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/39\">",
"     39",
"    </a>",
"    ]. The addition of the immunoperoxidase assay increased the sensitivity of testing from 52 to 83 percent.",
"   </p>",
"   <p>",
"    Of note, immunohistochemical findings consistent with OCP do not definitively rule out all other possible diagnoses. Epidermolysis bullosa acquisita and linear IgA bullous dermatosis, both of which may involve skin and ocular tissue, present with similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, other diagnostic clues are utilized to distinguish OCP from these disorders. The presence of prominent milia formation in skin lesions and the detection of antibodies against type VII collagen via enzyme-linked immunosorbent assay, immunoblotting, or immunoprecipitation support a diagnosis of epidermolysis bullosa acquisita. Predominant linear IgA binding at the basement membrane zone in combination with classic skin lesions resembling a &ldquo;cluster of jewels&rdquo; suggests the possibility of linear IgA bullous dermatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2198445\">",
"    <span class=\"h2\">",
"     Indirect immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating antibodies against the basement membrane zone are less consistently detected in patients with cicatricial pemphigoid than in patients with bullous pemphigoid, and are of little value for diagnosis. Reported rates of antibody detection vary widely, and the probability of a positive result may be affected by the type of technique performed and by individual patient characteristics such as the level of disease activity and sites of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913538\">",
"    <span class=\"h2\">",
"     Other laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific laboratory assays are useful for monitoring the activity of OCP. Although one study found increased levels of tumor necrosis factor (TNF)-alpha and decreased levels of interleukin (IL)-6 in sera from patients with active OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/43\">",
"     43",
"    </a>",
"    ], additional studies are necessary to determine whether these assays or any other serologic tests are clinically useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378908\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to OCP, a wide variety of other ocular disorders can present with conjunctival inflammation or scarring. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Conjunctivitis and conjunctival scarring",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Toxic epidermal necrolysis or Stevens-Johnson syndrome sequelae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epidermolysis bullosa acquisita",
"     </li>",
"     <li>",
"      Linear IgA bullous disease with cicatrizing conjunctivitis",
"     </li>",
"     <li>",
"      Bullous systemic lupus erythematosus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H10#H10\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Bullous skin lesions'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenoviral conjunctivitis sequelae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link&amp;anchor=H6#H6\">",
"       \"Conjunctivitis\", section on 'Viral conjunctivitis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paraneoplastic pemphigus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"       \"Paraneoplastic pemphigus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sebaceous cell carcinoma of the conjunctiva (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\", section on 'Sebaceous carcinoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intraepithelial epithelioma (squamous cell carcinoma of the conjunctiva)",
"     </li>",
"     <li>",
"      Corynebacterium diphtheriae conjunctivitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctival scarring",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Damage from ionizing radiation",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Porphyria cutanea tarda (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=see_link\">",
"       \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Progressive systemic sclerosis (scleroderma) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital ichthyosiform erythroderma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H7#H7\">",
"       \"The genodermatoses\", section on 'Congenital ichthyosiform erythroderma'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical history and assessment of other signs and symptoms are often useful for narrowing the differential diagnosis. If OCP remains in the differential, a biopsy of involved skin or mucosal tissues can be of value. (See",
"    <a class=\"local\" href=\"#H2913529\">",
"     'Establishing the diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464168\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with known or suspected OCP require referral to an ophthalmologist, preferably one with significant experience in this disease. Additionally, treatment should be managed by a clinician with expertise in immunosuppressive therapy, such as an ophthalmologist, dermatologist, rheumatologist, hematologist, or other clinician who is comfortable with this role.",
"   </p>",
"   <p>",
"    Continued ophthalmology follow-up is essential for evaluating the response to therapy. Moreover, the presence of extraocular involvement warrants assessment and follow-up by specific clinical specialists based upon the sites of disease (eg, dermatologist, dentist, otolaryngologist, or gastroenterologist). (See",
"    <a class=\"local\" href=\"#H378771\">",
"     'Extraocular involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913554\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of treatment in OCP is the prevention of scarring and vision loss. Whenever possible, patients should be managed by clinicians who have experience in treating this disease.",
"   </p>",
"   <p>",
"    The most important therapeutic interventions are the initiation of systemic immunomodulatory drugs to suppress conjunctival inflammation and the implementation of practices that minimize secondary ocular damage. While patients with mild to moderate conjunctival inflammation and slowly progressing disease can often be managed with ocular care and conventional immunomodulatory therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , patients with more aggressive or refractory disease typically require treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . In addition, initial studies suggest that intravenous immune globulin (IVIG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may have benefits for severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192358\">",
"    <span class=\"h2\">",
"     Ocular care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of nonpharmacologic measures are beneficial in the management of OCP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ocular lubrication",
"      </strong>",
"      &ndash; Xerophthalmia (dry eye) can lead to corneal damage, and the liberal use of ocular lubricants may help to prevent vision loss. Punctual plugs and punctual cautery, which prevent drainage of liquid from the eye, also can be helpful in the treatment of xerophthalmia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Prevention and treatment of infection",
"      </strong>",
"      &ndash; Patients with OCP are at increased risk for ocular infections due to the presence of a compromised ocular surface [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/44\">",
"       44",
"      </a>",
"      ]. The use of lid hygiene techniques on a daily basis may minimize the occurrence of ocular infections [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"       34",
"      </a>",
"      ]. We instruct patients to apply warm compresses for two minutes followed by vertical lid massage (10 strokes downward on the upper lid and 10 strokes upward on the lower lid) twice daily. This procedure expresses the lipid contents of the meibomian glands. Prompt identification and treatment of infections also is important.",
"     </li>",
"     <li>",
"      <strong>",
"       Eyelash removal",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Injury to the cornea as a result of trichiasis (inward turning of the eyelashes) can lead to visual impairment or blindness if left untreated. Eyelashes can be removed temporarily with manual epilation or permanently with cryoepilation. Cryoepilation should be performed when the disease is well-controlled to reduce the risk for procedure-related exacerbations of OCP [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34,44\">",
"       34,44",
"      </a>",
"      ]. Other potential adverse effects of cryoepilation include ocular edema and depigmentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192070\">",
"    <span class=\"h2\">",
"     Mild to moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, an international consensus panel of experts released recommendations for the medical management of patients with mucous membrane pemphigoid, which included patients with OCP. Based upon a review of the published literature and clinical experience, the consensus panel concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (50 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 weeks) was an appropriate initial therapy for patients with mild ocular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ]. A systematic review of randomized trials and uncontrolled studies also found evidence to support the use of dapsone in cicatricial pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are relatively fewer data on other systemic therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , these agents have also been used successfully by clinicians (including ourselves) for patients with OCP. No randomized trials have been performed that compare the efficacy of these therapies in OCP. Thus, factors such as concern for drug adverse effects, patient tolerance, drug availability, and drug cost heavily influence the choice of therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dapsone",
"      </strong>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"      is a sulfonamide antibiotic with antiinflammatory properties and proven efficacy in OCP [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5,6,32,45\">",
"       5,6,32,45",
"      </a>",
"      ]. The benefit of dapsone for ocular involvement was documented in a 12-week randomized trial in which 40 patients with stage III (see",
"      <a class=\"local\" href=\"#H378785\">",
"       'Staging'",
"      </a>",
"      above), biopsy-proven OCP were treated with either dapsone (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"       5",
"      </a>",
"      ]. Among the 20 patients treated with dapsone, 14 (70 percent) had complete suppression of conjunctival inflammation and scar formation. All of the patients treated with cyclophosphamide responded, but we reserve the use of cyclophosphamide for patients with severe or refractory disease. (See",
"      <a class=\"local\" href=\"#H192078\">",
"       'Severe or refractory disease'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Dapsone was also effective in a retrospective study in which the majority of patients had stage III, biopsy-proven OCP [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/6\">",
"       6",
"      </a>",
"      ]. Dapsone (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for at least three months) inhibited cicatrization in 31 of 69 patients (45 percent), including 26 of 28 patients with milder conjunctival inflammation defined as &lt;2+ severity on a 0 to 4+ scale (93 percent).",
"      <br/>",
"      <br/>",
"      Dapsone is typically administered in doses of 50 to 200 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"       32",
"      </a>",
"      ]. A 12-week period is a reasonable trial of therapy; alternative therapy should be considered if no response is observed after this time [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"       32",
"      </a>",
"      ]. Hemolytic anemia is a common adverse effect of dapsone that occurs to some degree in most patients who take dapsone but can be catastrophic in individuals with glucose-6-phosphate (G6PD) deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. In addition, idiosyncratic leukopenia and aplastic anemia may occur in the first three months of treatment; thus, patients must receive frequent hematologic monitoring early in the course of therapy. Methemoglobinemia, another potential adverse effect of dapsone, is a dose-dependent event unrelated to G6PD status.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      and sulfapyridine are additional sulfonamide agents that have been used in the management of patients with OCP [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. These agents may be less effective than dapsone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Methotrexate",
"      </strong>",
"      <strong>",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      is a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      antagonist. Methotrexate (5 to 25 mg given once weekly) was effective in a retrospective study of 17 patients with non-drug-induced OCP (12 patients) or drug-induced OCP (5 patients). Fifteen patients (88 percent, including all patients with drug-induced disease) achieved or maintained complete control of inflammation and 12 out of 17 patients (71 percent, including all but one patient with drug-induced disease) had no progression of cicatrization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/50\">",
"       50",
"      </a>",
"      ]. A potential limitation of this study is that only four patients had biopsy-proven OCP.",
"      <br/>",
"      <br/>",
"      Gastrointestinal distress, oral ulcers, myelosuppression, hepatotoxicity, pulmonary fibrosis, and renal toxicity are potential adverse effects of methotrexate. The coadministration of folic acid may lessen the gastrointestinal symptoms and oral ulcers. Dose adjustments are necessary if methotrexate must be administered in patients with renal insufficiency. The drug also is teratogenic and is relatively contraindicated in patients who abuse alcohol or who have preexisting liver disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mycophenolate",
"      </strong>",
"      <strong>",
"       mofetil",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil is an immunosuppressive agent that reversibly inhibits de novo purine synthesis via inhibition of the enzyme inosine monophosphate dehydrogenase. In a retrospective study in which mycophenolate mofetil (500 to 1000 mg twice daily) was given to 34 patients who had failed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and a sulfonamide or who received mycophenolate mofetil as a step-down therapy after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , the drug was beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/48\">",
"       48",
"      </a>",
"      ]. Out of 46 treatment episodes in which mycophenolate mofetil was the principal treatment agent, 59 percent were associated with complete clinical resolution of conjunctival inflammation. When only treatment episodes in patients with biopsy-proven disease were considered (11 episodes), the response rate rose to 73 percent.",
"      <br/>",
"      <br/>",
"      Mycophenolate mofetil is generally a well-tolerated drug, with gastrointestinal distress (eg, nausea, vomiting, diarrhea) as its most common associated adverse effect. Additionally, mycophenolate mofetil may induce cytopenia and the drug has teratogenic effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link&amp;anchor=H4#H4\">",
"       \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Azathioprine",
"      </strong>",
"      <strong>",
"      </strong>",
"      &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      , a purine derivative that exerts immunosuppressive effects through the inhibition of RNA and DNA synthesis and repair, has been effective for OCP in case reports and retrospective studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/6,48,51,52\">",
"       6,48,51,52",
"      </a>",
"      ]. In a retrospective study in which 60 patients received azathioprine as principal therapy after failure to respond sufficiently to a sulfonamide or as a step-down therapy after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , azathioprine controlled ocular inflammation in 47 percent of 80 treatment episodes in all patients and 48 percent of 37 treatment episodes in patients with biopsy-proven OCP [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Bone marrow suppression is a potential severe adverse effect of azathioprine which may be related to the activity of thiopurine methyltransferase (TPMT), an enzyme involved in the metabolism of the drug. The assessment of TPMT activity should be performed prior to the administration of azathioprine. Dose adjustments may be necessary based upon the result. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"       \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192078\">",
"    <span class=\"h2\">",
"     Severe or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive treatment is warranted for patients with severe or rapidly progressive OCP to minimize scarring and visual loss. Based upon the limited available data, combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is highly effective and is the treatment of choice for severe OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/6,7,32\">",
"     6,7,32",
"    </a>",
"    ]. Newer evidence indicates that intravenous immune globulin (IVIG) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    used independently or together may also be effective.",
"   </p>",
"   <p>",
"    Although systemic glucocorticoids are sometimes utilized to suppress acute inflammation in patients with OCP, they are",
"    <strong>",
"     not",
"    </strong>",
"    recommended as primary therapy due to the multiple adverse effects of long-term treatment and the high likelihood for disease relapse following tapering or discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. The preferred role of systemic glucocorticoids is as adjunctive therapy while awaiting the onset of action of other agents in patients with severe or rapidly progressive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192135\">",
"    <span class=\"h3\">",
"     Cyclophosphamide plus prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is an alkylating agent commonly used as an antineoplastic agent in oncology. The immunosuppressive properties of cyclophosphamide account for its beneficial effects in autoimmune blistering disease.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is supported by two randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a six-month randomized trial, 24 patients with bilateral stage III, biopsy-proven OCP were treated with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or prednisone plus a placebo pill [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"       5",
"      </a>",
"      ]. Prednisone was administered as 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for one week followed by a taper over 12 weeks to 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day. Prednisone was subsequently discontinued in the cyclophosphamide group.",
"      <br/>",
"      <br/>",
"      By eight weeks, all 12 patients treated with cyclophosphamide and prednisone achieved complete resolution of conjunctival inflammation. In addition, progression of scarring did not occur in the cyclophosphamide group during the course of the study. In contrast, only 5 out of 12 patients in the prednisone group had complete resolution of conjunctival inflammation, and, among those who responded, disease recurred when the dose fell below 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day.",
"     </li>",
"     <li>",
"      In a 12-week randomized trial in which 40 patients with stage III, biopsy-proven OCP were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), all 20 patients treated with cyclophosphamide exhibited resolution of clinically evident inflammation and no patients had progression of conjunctival scarring [",
"      <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"       5",
"      </a>",
"      ]. In contrast, similar results were observed in only 14 out of 20 patients treated with dapsone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    can be administered orally or intravenously. A response to therapy takes approximately six to eight weeks, which provides the rationale for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. We typically begin intravenous cyclophosphamide therapy with 1",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given every two weeks, and adjust the dose according to the degree of resultant leukopenia. We aim to maintain the white blood cell count above",
"    <span class=\"nowrap\">",
"     3000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    the absolute neutrophil count above",
"    <span class=\"nowrap\">",
"     1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    and the platelet count above",
"    <span class=\"nowrap\">",
"     70,000/&mu;L.",
"    </span>",
"    When utilizing oral cyclophosphamide therapy we prescribe initial doses of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"     32",
"    </a>",
"    ]. Prednisone (1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is initiated at the same time as cyclophosphamide therapy. Once improvement is achieved, we taper the prednisone over the course of approximately three months.",
"   </p>",
"   <p>",
"    As noted above, leukopenia is expected during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and a complete blood count should be monitored weekly for the first two to three months of therapy and at least monthly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/53\">",
"     53",
"    </a>",
"    ]. Gastrointestinal distress, hemorrhagic cystitis, bladder cancer, infections, hair loss, and reproductive problems such as amenorrhea, premature ovarian failure, and azoospermia also can occur with cyclophosphamide. The drug is teratogenic and, thus, is contraindicated in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the potential long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we limit the duration of treatment with cyclophosphamide to 12 months. Patients who reach this duration of therapy are transitioned to other immunomodulatory agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192142\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) may be effective for the treatment of OCP that is refractory to other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. In a nonrandomized study of 16 patients with OCP, the administration of IVIG with gradual withdrawal of conventional therapy was associated with a shorter time to clinical remission compared with the time required in patients who were maintained on conventional therapy (4 versus 8.5 months). In addition, total control of disease activity was achieved in all patients treated with IVIG compared with only three out of eight patients who continued conventional therapy. Sustained remissions of 24 to 48 months have been reported after completion of IVIG therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the initial cost of treatment with IVIG can be limiting, a retrospective study in the United States that compared the cost of IVIG and conventional immunosuppressive therapy in patients with severe mucous membrane pemphigoid found that the overall cost of disease management was lower in patients treated with IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects of IVIG include hypersensitivity reactions, headache, vasculitis, aseptic meningitis, renal failure, myocardial infarction, and thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192225\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a chimeric monoclonal antibody that targets the CD20 antigen on pre-B and mature B lymphocytes. Uncontrolled studies and a case report support its efficacy in OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/59-62\">",
"     59-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 25 patients with biopsy-proven, severe, refractory mucous membrane pemphigoid that included 10 patients with active stage III or IV OCP,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly for four weeks for one or two cycles) was associated with resolution of conjunctival inflammation in 9 of the 10 patients after one treatment cycle and in all patients after two cycles (median time to remission 10 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/61\">",
"     61",
"    </a>",
"    ]. Long-lasting improvement after rituximab occurred in 76 percent of the patients with mucous membrane pemphigoid, with maintenance of complete or partial responses during a median follow-up period of 24 months.",
"   </p>",
"   <p>",
"    Of note, two patients who were simultaneously treated with systemic immunosuppressive therapy developed severe, fatal infections. Additional potential side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include nausea, serum sickness-like reactions, and infusion reactions. A boxed warning on the drug label of rituximab has been mandated by the US Food and Drug administration due to reports of progressive multifocal leukoencephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and IVIG may be of value for the management of patients with severe OCP. In a retrospective study of 12 patients with OCP that was refractory to conventional therapies, disease progression ceased in the six patients who were treated with rituximab and IVIG and in none of the patients who were given other aggressive therapies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IVIG) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional studies are necessary to explore the efficacy of rituximab with and without IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192251\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other systemic therapies that have been used for patients with severe or refractory OCP include subcutaneous cytosine arabinoside and daclizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ]. Oral cyclosporine and oral tacrolimus are",
"    <strong>",
"     poorly effective",
"    </strong>",
"    for arresting disease progression in OCP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379217\">",
"    <span class=\"h2\">",
"     Local therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local therapy with agents such as topical corticosteroids, topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and topical or subconjunctival",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C has a limited role in the management of OCP, as they have no effect on suppressing the underlying immune dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5,65-67\">",
"     5,65-67",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H379224\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical procedures are used to treat ocular damage related to OCP. Examples include the removal of symblephara that inhibit lid function, the repair of entropion, and the use of surgical procedures that address visual impairment due to corneal damage. Corneal procedures that have been used in OCP include amniotic membrane transplantation, limbal stem cell transplantation, lamellar or penetrating keratoplasty (corneal transplants), and the placement of keratoprostheses (artificial corneas) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the performance of ocular surgery, complete control of inflammation should be obtained with immunomodulatory drugs to improve the likelihood of a good surgical outcome. In addition, the level of immunosuppression is typically increased in the perioperative period to reduce the risk of surgery-induced disease exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913561\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND CESSATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, OCP is a slow, progressive disease process. Advancement of the disease from initial conjunctival inflammation to end stage disease characterized by bilateral blindness may take 10 to 30 or more years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"     5",
"    </a>",
"    ]. However, some patients progress more quickly, and periods of severe exacerbation and rapid scarring may occur. Early identification of the disease and the prompt implementation of appropriate treatment are key factors in the prevention of adverse disease sequelae.",
"   </p>",
"   <p>",
"    Although OCP is a chronic, relapsing disease, long-term remission amounting to cure of the disease is possible in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/7,48,68\">",
"     7,48,68",
"    </a>",
"    ]. In one series of 104 patients followed for an average of four years, prolonged periods of remission off therapy occurred in approximately one-third of patients (average length of remission of 34 months, range 2 to 75 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/2/4138/abstract/63,68\">",
"     63,68",
"    </a>",
"    ]. Since disease relapse is unpredictable, continued long-term follow-up of patients in remission is essential.",
"   </p>",
"   <p>",
"    We proceed with attempts to cease therapy in patients in whom disease activity (conjunctival inflammation) has been quiescent for two years. Inflammation related to trichiasis or glandular dysfunction may be confused with active pemphigoid, and interventions to minimize the effects of such findings are important for the accurate assessment of disease status. (See",
"    <a class=\"local\" href=\"#H192358\">",
"     'Ocular care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2913568\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular cicatricial pemphigoid (OCP) is a form of mucous membrane pemphigoid that manifests as a chronic cicatrizing conjunctivitis. Early diagnosis and treatment are essential for the prevention of severe scarring and blindness. (See",
"      <a class=\"local\" href=\"#H2913441\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OCP is a relatively uncommon disorder that preferentially affects the elderly. Women are more likely to be affected than men. OCP rarely occurs in children. (See",
"      <a class=\"local\" href=\"#H2913448\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of OCP is likely to involve the stimulation of an inflammatory response by autoantibodies that bind to normal components of the conjunctival basement membrane zone. The &beta;4 peptide of &alpha;6&beta;4 integrin appears to be a frequent target antigen. (See",
"      <a class=\"local\" href=\"#H2913490\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical findings in OCP vary according to the stage of the disease. Disease initially manifests as a chronic conjunctivitis and progresses to conjunctival fibrosis manifesting and conjunctival contracture or symblepharon (",
"      <a class=\"graphic graphic_picture graphicRef65724 graphicRef78279 graphicRef54207 \" href=\"UTD.htm?5/49/5914\">",
"       picture 1A-C",
"      </a>",
"      ). Xerophthalmia (dry eye) and trichiasis (inward turning of the eyelashes) are additional common findings (",
"      <a class=\"graphic graphic_picture graphicRef75647 \" href=\"UTD.htm?24/56/25477\">",
"       picture 2",
"      </a>",
"      ). Corneal damage resulting in visual impairment may also occur (",
"      <a class=\"graphic graphic_picture graphicRef66981 \" href=\"UTD.htm?22/61/23508\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2913497\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatments used for the management of OCP have multiple adverse effects, and confirmation of the diagnosis with immunohistochemical studies on biopsy specimens should be performed whenever feasible. The characteristic immunohistochemical finding is linear deposition of IgG, IgA, or C3 along the basement membrane zone. Negative direct immunofluorescence results are common and should",
"      <strong>",
"       not",
"      </strong>",
"      be used to rule out the diagnosis. (See",
"      <a class=\"local\" href=\"#H2913529\">",
"       'Establishing the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with extraocular skin or mucosal lesions, initial biopsies for diagnosis can be performed at those sites. Conjunctival biopsies are necessary in patients with disease limited to the ocular mucosa or in those in whom the diagnosis is highly suspected despite negative extraocular biopsy results. (See",
"      <a class=\"local\" href=\"#H2828114\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with known or suspected OCP require referral to an ophthalmologist. Whenever possible, patients should be managed by clinicians experienced in the management of this disease. (See",
"      <a class=\"local\" href=\"#H464168\">",
"       'Indications for referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic immunomodulatory therapy and eye care practices aimed at reducing the risk for scarring and visual impairment are the most important components of the management for patients with OCP. For patients with mild to moderate OCP, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      based upon the evidence in support of its efficacy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Other effective therapies that have been less studied include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . Topical therapy alone should",
"      <strong>",
"       not",
"      </strong>",
"      be used for the management of OCP. (See",
"      <a class=\"local\" href=\"#H2913554\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H192070\">",
"       'Mild to moderate disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe, rapidly progressive, or refractory disease require aggressive treatment. We recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). IVIG and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      are additional treatments that have shown promising results in early studies. Additional studies are necessary to determine whether these interventions should be considered first-line treatment options for severe OCP. (See",
"      <a class=\"local\" href=\"#H192078\">",
"       'Severe or refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/1\">",
"      Bettelheim H, Kraft D, Zehetbauer G. [On the so-called ocular pemphigus (pemphigus ocularis, pemphigus conjunctivae)]. Klin Monbl Augenheilkd 1972; 160:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/2\">",
"      Hardy WF, Lamb HD. Essential shrinkage of the conjunctiva with report of two cases. Am J Ophthalmol 1917; 34:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/3\">",
"      Smith RC, Myers EA, Lamb HD. Ocular and oral pemphigus: Report of case with anatomic findings in eyeball. Arch Ophthalmol 1934; 11:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/4\">",
"      BEDELL AJ. OCULAR PEMPHIGUS: A CLINICAL PRESENTATION OF KODACHROMES. Trans Am Ophthalmol Soc 1964; 62:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/5\">",
"      Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/6\">",
"      Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/7\">",
"      Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 2008; 115:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/8\">",
"      Kharfi M, Khaled A, Anane R, et al. Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 2010; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/9\">",
"      Chan RY, Bhol K, Tesavibul N, et al. The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1999; 40:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/10\">",
"      Tyagi S, Bhol K, Natarajan K, et al. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996; 93:14714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/11\">",
"      Kumari S, Bhol KC, Simmons RK, et al. Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. Invest Ophthalmol Vis Sci 2001; 42:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/12\">",
"      Fujimoto W, Toi Y, Okazaki F, et al. Anti-epiligrin cicatricial pemphigoid with IgG autoantibodies to the beta and gamma subunits of laminin 5. J Am Acad Dermatol 1999; 40:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/13\">",
"      Kirtschig G, Marinkovich MP, Burgeson RE, Yancey KB. Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. J Invest Dermatol 1995; 105:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/14\">",
"      B&eacute;dane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/15\">",
"      Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996; 106:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/16\">",
"      Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol 1996; 107:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/17\">",
"      Smith EP, Taylor TB, Meyer LJ, Zone JJ. Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 1993; 101:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/18\">",
"      Bhol KC, Dans MJ, Simmons RK, et al. The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J Immunol 2000; 165:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/19\">",
"      Razzaque MS, Foster CS, Ahmed AR. Role of connective tissue growth factor in the pathogenesis of conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003; 44:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/20\">",
"      Elder MJ, Dart JK, Lightman S. Conjunctival fibrosis in ocular cicatricial pemphigoid--the role of cytokines. Exp Eye Res 1997; 65:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/21\">",
"      Lambiase A, Micera A, Mantelli F, et al. T-helper 17 lymphocytes in ocular cicatricial pemphigoid. Mol Vis 2009; 15:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/22\">",
"      Haider N, Neuman R, Foster CS, Ahmed AR. Report on the sequence of DQB1*0301 gene in ocular cicatricial pemphigoid patients. Curr Eye Res 1992; 11:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/23\">",
"      Ahmed AR, Foster S, Zaltas M, et al. Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci U S A 1991; 88:11579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/24\">",
"      Patten JT, Cavanagh HD, Allansmith MR. Induced ocular pseudopemphigoid. Am J Ophthalmol 1976; 82:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/25\">",
"      Hirst LW, Werblin T, Novak M. Drug induced cicatrizing conjunctivitis simulating ocular pemphigoid. Cornea 1982; 1:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/26\">",
"      Rahi AH, Chapman CM, Garner A, Wright P. Pathology of practolol-induced ocular toxicity. Br J Ophthalmol 1976; 60:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/27\">",
"      Gibran SK. Unilateral drug-induced ocular pseudopemphigoid. Eye (Lond) 2004; 18:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/28\">",
"      Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid. A spectrum of diseases. Arch Ophthalmol 1987; 105:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/29\">",
"      Pouliquen Y, Patey A, Foster CS, et al. Drug-induced cicatricial pemphigoid affecting the conjunctiva. Light and electron microscopic features. Ophthalmology 1986; 93:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/30\">",
"      Butt Z, Kaufman D, McNab A, McKelvie P. Drug-induced ocular cicatricial pemphigoid: a series of clinico-pathological reports. Eye (Lond) 1998; 12 ( Pt 2):285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/31\">",
"      Bhol K, Mohimen A, Neumann R, et al. Differences in the anti-basement membrane zone antibodies in ocular and pseudo-ocular cicatricial pemphigoid. Curr Eye Res 1996; 15:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/32\">",
"      Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/33\">",
"      Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991; 266:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/34\">",
"      Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/35\">",
"      Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/36\">",
"      Tauber J, Jabbur N, Foster CS. Improved detection of disease progression in ocular cicatricial pemphigoid. Cornea 1992; 11:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/37\">",
"      Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981; 88:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/38\">",
"      Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/39\">",
"      Power WJ, Neves RA, Rodriguez A, et al. Increasing the diagnostic yield of conjunctival biopsy in patients with suspected ocular cicatricial pemphigoid. Ophthalmology 1995; 102:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/40\">",
"      Franklin RM, Fitzmorris CT. Antibodies against conjunctival basement membrane zone. Occurrence in cicatricial pemphigoid. Arch Ophthalmol 1983; 101:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/41\">",
"      Chan LS, Yancey KB, Hammerberg C, et al. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Arch Dermatol 1993; 129:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/42\">",
"      Hoang-Xuan T, Robin H, Demers PE, et al. Pure ocular cicatricial pemphigoid. A distinct immunopathologic subset of cicatricial pemphigoid. Ophthalmology 1999; 106:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/43\">",
"      Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993; 34:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/44\">",
"      Chang JH, McCluskey PJ. Ocular cicatricial pemphigoid: manifestations and management. Curr Allergy Asthma Rep 2005; 5:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/45\">",
"      Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/46\">",
"      Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002; 109:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/47\">",
"      Wertheim MS, Males JJ, Cook SD, Tole DM. Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid. Br J Ophthalmol 2006; 90:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/48\">",
"      Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/49\">",
"      Elder MJ, Leonard J, Dart JK. Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/50\">",
"      McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/51\">",
"      Lugovi�� L, Buljan M, Situm M, et al. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007; 15:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/52\">",
"      Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 1974; 90:183.",
"     </a>",
"    </li>",
"    <li>",
"     Perlis C, Pan TD, McDonald CJ. Cytotoxic agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc, Philadelphia 2007. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/54\">",
"      Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/55\">",
"      Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/56\">",
"      Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/57\">",
"      Letko E, Bhol K, Foster SC, Ahmed RA. Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study. Curr Eye Res 2000; 21:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/58\">",
"      Daoud Y, Amin KG, Mohan K, Ahmed AR. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study. Ann Pharmacother 2005; 39:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/59\">",
"      Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/60\">",
"      Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/61\">",
"      Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/62\">",
"      Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/63\">",
"      Foster CS, Neumann R, Tauber J. Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid. Doc Ophthalmol 1992; 82:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/64\">",
"      Letko E, Ahmed AR, Foster CS. Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 2001; 239:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/65\">",
"      Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol 2005; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/66\">",
"      Hall VC, Liesegang TJ, Kostick DA, Lookingbill DP. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/67\">",
"      Alonso A, Bignone ML, Brunzini M, Brunzini R. Ocular autoimmune pemphigoid and cyclosporin A. Allergol Immunopathol (Madr) 2006; 34:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/2/4138/abstract/68\">",
"      Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991; 98:858.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15590 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-218.28.111.102-E73EFF4BA8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4138=[""].join("\n");
var outline_f4_2_4138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2913568\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913441\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913448\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913490\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913497\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378742\">",
"      Ocular findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378785\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378771\">",
"      Extraocular involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913529\">",
"      ESTABLISHING THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2828114\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2198362\">",
"      - Hematoxylin and eosin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H378882\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2198445\">",
"      Indirect immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2913538\">",
"      Other laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H378908\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464168\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913554\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192358\">",
"      Ocular care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192070\">",
"      Mild to moderate disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H192078\">",
"      Severe or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192135\">",
"      - Cyclophosphamide plus prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192142\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192225\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H192251\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H379217\">",
"      Local therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H379224\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913561\">",
"      PROGNOSIS AND CESSATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2913568\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15590|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/16/29955\" title=\"picture 1A\">",
"      Ocular cicatricial pemphigoid stage 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/35/4659\" title=\"picture 1B\">",
"      Ocular cicatricial pemphigoid stage 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/12/31937\" title=\"picture 1C\">",
"      Ocular cicatricial pemphigoid stage 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/56/25477\" title=\"picture 2\">",
"      Trichiasis in ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/61/23508\" title=\"picture 3\">",
"      Ocular cicatricial pemphigoid stage 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/41/13972\" title=\"picture 4\">",
"      Ocular cicatricial pemphigoid histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/37/34399\" title=\"picture 5\">",
"      Ocular cicatricial pemphigoid squamous metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/51/26422\" title=\"picture 6\">",
"      Ocular cicatricial pemphigoid pathology PAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/2/27683\" title=\"picture 7\">",
"      Ocular cicatricial pemphigoid DIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/49/3856\" title=\"picture 8\">",
"      Ocular cicatricial pemphigoid immunoperoxidase",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=related_link\">",
"      Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_2_4139="Timing of first ultrasound appearance of pregnancy landmarks";
var content_f4_2_4139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of first appearance of gestational landmarks on transvaginal ultrasound examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Landmark",
"       </td>",
"       <td class=\"subtitle1\">",
"        First appearance on transvaginal ultrasound examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational sac",
"       </td>",
"       <td>",
"        4.5 to 5 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yolk sac",
"       </td>",
"       <td>",
"        5 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac activity",
"       </td>",
"       <td>",
"        5.5 to 6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurable crown-rump length",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4139=[""].join("\n");
var outline_f4_2_4139=null;
var title_f4_2_4140="Classification ileal pouch";
var content_f4_2_4140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of ileal pouch disorders and associated complications",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"9\">",
"       Surgical and mechanical",
"      </td>",
"      <td>",
"       Anastomotic leaks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pelvic sepsis and abscess",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pouch sinuses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pouch fistulae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Strictures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Afferent limb syndrome and efferent limb syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infertility and sexual dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Portal vein thrombi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pouch prolapse, twisted pouch bleeding, sphincter injury or dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"5\">",
"       Inflammatory and infectious",
"      </td>",
"      <td>",
"       Pouchitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cuffitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CD of the pouch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Proximal small-bowel bacterial overgrowth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory polyps",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Functional",
"      </td>",
"      <td>",
"       Irritable pouch syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anismus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudo-obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"2\">",
"       Dysplastic and neoplastic",
"      </td>",
"      <td>",
"       Dysplasia or cancer of the pouch",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dysplasia or cancer of the anastomosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Systemic and metabolic",
"      </td>",
"      <td>",
"       Anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bone loss",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitamin B-12 deficiency",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shen, B, Remzi, FH, Lavery, IC, et al. A Proposed Classification of Ileal Pouch Disorders and Associated Complications After Restorative Proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145. Copyright &copy;2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4140=[""].join("\n");
var outline_f4_2_4140=null;
var title_f4_2_4141="Diseases associated with T-LGL leukemia";
var content_f4_2_4141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diseases associated with T-cell large granular lymphocyte leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Associated diseases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Autoimmune diseases",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        15 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rheumatoid arthritis",
"       </td>",
"       <td>",
"        11 to 36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sjogren syndrome",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymyositis",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymyalgia rheumatica",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multineuritis",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasculitis",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocrinopathy",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Celiac disease",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic inflammatory bowel disease",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy",
"       </td>",
"       <td>",
"        Case report",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Autoimmune cytopenia*",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        5 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pure red cell aplasia",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autoimmune hemolytic anemia",
"       </td>",
"       <td>",
"        &lt;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiopathic thrombocytopoenic purpura",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclic neutropenia",
"        </strong>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pulmonary hypertension",
"        </strong>",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Neoplasia",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        &lt;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solid tumors",
"       </td>",
"       <td>",
"        &lt;4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myelodysplasia",
"       </td>",
"       <td>",
"        &lt;4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B-cell malignancies",
"       </td>",
"       <td>",
"        5 to 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CML treated with dasatinib",
"       </td>",
"       <td>",
"        Recently described",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Viral infection",
"        </strong>",
"        (HIV, CMV, HCV, EBV)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Post-transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solid and hematopoietic stem cell transplantation",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CML: chronic myeloid leukemia; CMV: cytomegalovirus; HCV: hepatitis C virus; EBV: Epstein-Barr virus; CR: case report.",
"     <br>",
"      * Excluding chronic neutropenia.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764. Copyright &copy; 2011 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4141=[""].join("\n");
var outline_f4_2_4141=null;
var title_f4_2_4142="United States TB epidemiology (1980 to 1991)";
var content_f4_2_4142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Excess tuberculosis cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expected and observed tuberculosis cases in the United States from 1980 through 1991.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4142=[""].join("\n");
var outline_f4_2_4142=null;
var title_f4_2_4143="CT guided bone bx ant sacrum";
var content_f4_2_4143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT-guided bone biopsy of a sacral metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Safe access to biopsy of this bone metastasis in the anterior sacrum required an unusually long transiliac approach. The patient is lying prone and the needle is inserted through the buttock.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_2_4143=[""].join("\n");
var outline_f4_2_4143=null;
